CONFIDENTIAL  Page 1 of 55 
TI SOP 305 -A Protocol Template, Version 06  A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE -BLIND, VEHICLE -
CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 
CORTEXOLONE 17Î± -PROPI[INVESTIGATOR_229747] (CB -03-01) CREAM, 1% APPLIED 
TWICE DAILY FOR 12 WEEKS IN SUBJECTS WITH  
FACIAL ACNE VULGARIS  
 
SPONSOR PROTOCOL NUMB ER: CB-03-01/25  
TI PROTOCOL NUMBER:  171-7151 -304 
REGULATORY FILING NUMBER:  IND #112,137  
ORIGINAL PROTOCOL:  August 06, 2015  
FILENAME:  [CONTACT_206617]-03-01_25_pro_06Aug2015_v1.0  
SPONSOR:  Cassiopea S.p.A.1 
Via C. Colombo 1,  
[ZIP_CODE] Lainate (MI), Italy  
SPONSOR REPRESENTATIVES:  Luigi Moro, Ph.D., Chief Scientific Officer  
Louise Dube, Ph.D., Global Director of R&D  
MEDICAL MONITOR:  Daniel Pi[INVESTIGATOR_229748], M.D.  
Therapeutics, Inc.  
[ADDRESS_276480] 
San Diego, CA [ZIP_CODE] [PHONE_3562], ext. 107 (office) [PHONE_3183] (facsimile) [PHONE_4838] (cell) 
[EMAIL_4504] (email)  
PROJECT MANAGER:  Marietta Radona  
Therapeutics, Inc.  
[ADDRESS_276481] San Diego, CA [ZIP_CODE] [PHONE_3562], ext. 171 (office) [PHONE_3183] (facsimile)  
[EMAIL_3240] (email)  
 
24 Hour Emergency Telephone Number 
[PHONE_4838] 
Therapeutics, Incorporated  
[ADDRESS_276482], San Diego, CA [ZIP_CODE] 
The information contained in this document is confidential and proprietary 
property of Cassiopea S.p.A. 
                                                 
1 Cassiopea S.p.A. was previously Cosmo Dermatos Srl (the current Sponsor for IND #112,137).  
Product Name: [CONTACT_229808] 17Î±- Propi[INVESTIGATOR_16847] (CB -03-01) Protocol: CB-03-01/25 
Sponsor Name: [CONTACT_229771] S.p.A.  Protocol Date: August 06, [ADDRESS_276483](s). These disclosures may be made; providing the contents are not used in any other clinical 
study and they are not disclosed to any other person or entity without prior written 
consent from Cassiopea S.p.A . This condition does not apply to disclosure required by 
[CONTACT_24619]; however, I agree to give prompt notice to Cassiopea 
S.p.A. of any such disclosure. 
 
I understand the study may be terminated or enrollment suspended at any time by 
[CONTACT_229771] S.p.A., with or without cause, or by [CONTACT_28223]. 
 Any additional information added to this protocol is also confidential and proprietary to Cassiopea S.p.A. and must be treated in the same manner as the contents of this protocol. 
 ____________________________________ Printed Name [CONTACT_229809]  
 ____________________________________  _____________________ Investigator Signature       [CONTACT_229810]: CB-03-01/25    Site number:   ____  
 Version: 1.0  
Date of final version: August 06, [ADDRESS_276484] Name: [CONTACT_229808] 17Î±- Propi[INVESTIGATOR_16847] (CB -03-01) Protocol: CB-03-01/25 
Sponsor Name: [CONTACT_229771] S.p.A.  Protocol Date: August 06, 2015 
 
CONFIDENTIAL  Page 4 of 55 
TI SOP 305 -A Protocol Template, Version 06  PROTOCOL SYNOPSIS  
Title  A Phase 3, Multicenter, Randomized, Double -Blind, Vehicle -Controlled 
Study to Evaluate the Safety and Efficacy of Cortexolone 17Î±- Propi[INVESTIGATOR_16847] 
(CB-03-01) Cream, 1% Applied Twice Daily for [ADDRESS_276485] Articles  1. CB-03-01 (cortexolone 17Î± -propi[INVESTIGATOR_16847]) cream, 1%  
2. Vehicle cream  
Study Objective  The primary objective of this study is to determine the safety and efficacy of 
CB-03-01 cream, 1%, versus the vehicle cream applied twice daily for 12 
weeks in subjects with facial acne vulgaris.  
Study Design  Multicenter, randomized, double -blind, vehicle -controlled, parallel group 
comparison study.  
 
A separate open -label long -term extension study is planned. Subjects 
completing the treatment -phase of this trial will be offered the opportunity 
to participate in this follow -on study (CB -03-01/27). In this open label study, 
all subjects will apply the active medication (cortexolone 17Î± -propi[INVESTIGATOR_229749], 1%) twice daily for up to 9 additional months of treatment (for a total 
of up to 12 months; 0 or 3 months in the pi[INVESTIGATOR_9205] 3 trial and an 
additional 9 months in the open -label long -term extension study).  
Treatment Groups  Eligible subjects will be randomized (1:1) to one of two treatment groups: 
(1) CB -03-01 cream, 1% or (2) vehicle cream. All subjects (with supervision 
from parent/guardian, if needed) will apply the assigned test article twice -
daily to the entire face for 12 weeks.  
Duration of Treatment  12 weeks  
Duration of Study  12 weeks  
Study Population  Male  and female subjects 9 years or older with facial acne vulgaris (Grade 3 
or 4 on Investigatorâ€™s Global Assessment [IGA]).  
Total Number of 
Subjects  At least 700 subjects; [ADDRESS_276486] meet the following criteria:  
Product Name: [CONTACT_229808] 17Î±- Propi[INVESTIGATOR_16847] (CB -03-01) Protocol: CB-03-01/25 
Sponsor Name: [CONTACT_229771] S.p.A.  Protocol Date: August 06, [ADDRESS_276487] (UPT) at the Screening/Baseline Visit.  
2. Subject has provided written and verbal informed consent/assent. A 
subject under [ADDRESS_276488] provide writ ten informed assent and 
be accompanied by [CONTACT_85168]/consent signing. The parent or legal guardian must provide 
informed consent for the subject. If a subject becomes [ADDRESS_276489] has an Investigatorâ€™s Global Assessment (IGA) score of 3 or 4 
[0 (clear) to 4 (severe) scale].  
4. Subject has facial acne vulgaris, which can include the nose, with at least 
30 to a maximum of 75 inflammatory lesions (papules, pustules, and 
nodules) and 30 to a maximum of 100 n on-inflammatory lesions (open 
and closed comedones).  
5. Subject and parent/guardian (if applicable) are willing to comply with study instructions and r eturn to the clinic for required visits.
 
6. Subject has used the same type and brand of make- up, other facial 
products (exclusive of RX/OTC acne cleansers) and hair products (e.g., 
shampoo, gel, hair spray, mousse, etc.) for at least one (1) month prior 
to the Baseline Visit and agrees to continue his/her other general skin 
and hair care products and regimen for the entire study.  
Exclusion Criteria  A subject is ineligible to enter the study if he/she meets one or more of the 
following criteria:  
1. Subject is pregnant, lactating, or is planning to become pregnant during 
the study.  
2. Subject has any skin pathology or condition that could interfere with the evaluation of the test products or requires the use of interfering topi[INVESTIGATOR_229750]. 
3. Subject has greater than two (2) facial nodules.  
4. Subject has nodulocystic acne.  
5. Subject has any condition which, in the investigatorâ€™s opi[INVESTIGATOR_1649], would make it unsafe for the subject to participate in this research study.  
6. Subject i s currently enrolled in an investigation al drug or device study.  
                                                 
2 Defined as amenorrhea greater than 12 consecutive months.  
3 Hysterectomy, bilateral tubal ligation (at least six (6) months p rior to study entry), or bilateral 
oophorectomy.  
4 Highly effective contraception includes a) total abstinence, b) oral, injected, or implanted hormonal methods 
of contraception, c) intrauterine device (IUD), d) partner vasectomy (performed at least six (6) months prior to study entry), or e) double barrier methods of contraception [barrier methods include male or female condom, diaphragm with spermicidal foam/gel/film/vaginal suppository, cervical cap with spermicides, or contraceptive sponge].  
5 Women of childbearing potential (WOCBP) taking hormonal therapy for any reason exclusive for the 
treatment of acne (e.g., as contraception, etc.) must be on the same treatment for at least [ADDRESS_276490] eight (8) weeks prior to the start of the study.  
Product Name: [CONTACT_229808] 17Î±- Propi[INVESTIGATOR_16847] (CB -03-01) Protocol: CB-03-01/25 
Sponsor Name: [CONTACT_229771] S.p.A.  Protocol Date: August 06, [ADDRESS_276491] has  received  an investigational drug or has been treated with an 
investigational device within 30 days prior to the initiation of treatment 
(Baseline). 
8. Subject has facial hair that could interfere with the study assessments  in 
the opi[INVESTIGATOR_871].  
9. Subject and parent/guardian (if applicable) are unable to communicate or cooperate with the investigator due to language problems, poor mental 
development, or impaired cerebral function.  
10. Subject may be unreliable for th e study including subjects who engage 
in excessive alcohol intake or drug abuse, or subjects who are unable to 
return for scheduled follow -up visits.  
11. Subject has known hypersensitivity or previous allergic reaction to any 
of the active or inactive componen ts of the test articles (see Section 6.1). 
12. Subject has the need or plans to be exposed to artificial tanning devices 
or excessive sunlight during th e trial.  
13. Subject has used any of the following topi[INVESTIGATOR_900]-acne preparations or 
procedures on the face: 
â€¢ Topi[INVESTIGATOR_900]- acne treatments including, but not limited to, over -the-
counter (OTC) acne cleansers or treatments, benzoyl peroxide, 
antibiotics, azelaic  acid, sulfa based products, corticosteroids and 
salicylic acid within two (2) weeks of the initiation of treatment.  
â€¢ Retinoids, including tazarotene, adapalene, tretinoin, within four (4) weeks of the initiation of treatment.  
â€¢ Light treatments, microdermabrasion, or chemical peels within eight 
(8) weeks of the initiation of treatment.  
14. Subject has used the following systemic  anti-acne medications:  
â€¢ Corticosteroids (including intramuscular and intralesional injections) within four (4) weeks of the 
initiation of treatment. Inhaled, 
intranasal, or ocular corticosteroids are allowed if use is stable (stable 
use is defined as dose and frequency unchanged for at least four (4) 
weeks prior to the initiation of treatment).  
â€¢ Antibiotics within four (4) weeks  of the initiation of treatment with 
the exception of five (5) days or less of antibiotic therapy during this 
period, BUT with no antibiotics use permitted within one (1) week 
prior to the initiation of treatment.  
â€¢ Spi[INVESTIGATOR_229751] (8) weeks of t he initiation of treatment 
with the exception of five (5) days or less of spi[INVESTIGATOR_229752], BUT with no spi[INVESTIGATOR_229753] (1) week prior to the initiation of treatment.  
â€¢ Retinoid therapy within six (6) months o f the initiation of treatment.  
â€¢ Other systemic therapy which may materially affect the subjectâ€™s 
acne in the opi[INVESTIGATOR_871].  
Study Procedures  The study will consist of a Screening/Baseline Visit and three (3) scheduled 
visits.  
 
1. Visit 1 (Screening/Baseline):  At Visit 1, study staff will explain the 
study procedures and an informed consent/assent must be signed prior 
to the initiation of any study -related procedures. At this visit, consenting 
subjects will have their medical and dermatolog ical history, 
dermatologic exam, and inclusion/exclusion criteria reviewed to 
determine subject eligibility. Subjects that require a â€œwashoutâ€ period 
Product Name: [CONTACT_229808] 17Î±- Propi[INVESTIGATOR_16847] (CB -03-01) Protocol: CB-03-01/25 
Sponsor Name: [CONTACT_229771] S.p.A.  Protocol Date: August 06, 2015 
 
CONFIDENTIAL  Page 7 of 55 
TI SOP 305 -A Protocol Template, Version 06  prior to enrollment to meet inclusion/exclusion criteria requirements 
will be required to return to the clinic within 45 days to complete the 
remaining activities. Subjects who require â€œwashoutâ€ for longer than 45 days will be re -consented. A brief physical examination including vital 
signs, UPT (if applicable), electrocardiogram (ECG), Fitzpatrick Skin Type a ssessment, clinical evaluations (lesions counts, IGA, as well as 
baseline local skin reactions (LSRs) pre- application), and photographs 
will be performed at this visit. Prior and concomitant therapy and 
concomitant medications/procedures will be reviewed. Subjects will be 
randomized and assigned a test article kit number. Test article and 
Subject Diary will be dispensed. Subjects and parent/guardian (if 
applicable) will be instructed on how to apply the test article and to 
record applications in the Subject  Diary. The first dose will be applied 
during this visit under supervision of the investigator. Adverse events 
(AEs) and LSRs post -application will be assessed. The subject will be 
scheduled for the first follow -up visit.  
 
2. Visits 2 and 3 (Weeks 4 & 8) : Sub jects will return after the initial 
treatment for clinical evaluations (lesion counts, IGA, AEs, and LSRs), UPT (if applicable), and review of concomitant medications/procedures. Test article application and compliance will be reviewed (from Subject Diary) , test article and Subject Diary will be dispensed/returned (as 
required), and photography will be performed. The subject will be 
scheduled for the next follow -up visit.  
 
3. Visit 4 (Final Visit, Week 12 & Early Termination): Subjects will return 
for the fina l visit for review of concomitant medications/procedures, 
UPT (if applicable), ECG, clinical evaluations (lesion counts, IGA, AEs, and LSRs), and photography. All test article will be returned and 
compliance documented (from Subject Diary).  
Study Measurem ents Efficacy  will be assessed by [CONTACT_3470]:  
â€¢ Investigatorâ€™s Global Assessment (IGA) : Overall severity of acne 
using a five -point scale from 0 = clear to 4 = severe will be conducted 
at each visit. This is a static morphological scale that  refers to a point 
in time and not a comparison to Baseline.  
â€¢ Acne Lesion Counts:  Total lesions, including inflammatory lesions 
(papules, pustules, and nodules) and non- inflammatory lesions (open 
and closed comedones), on the face will be accurately counted , but 
recorded separately at each visit. 
 Safety  will be assessed by [CONTACT_229772] (Baseline, Weeks 4, 8, and 12, or at the end of treatment). ECGs will also be assessed at Baseline and  Week 12.  
 
LSRs including telangiectasia, skin atrophy, striae rubrae, erythema, edema, and scaling/dryness will be assessed by [CONTACT_229773] a 
five-point ordinal scale (0 = none, 1 = trace, 2 = mild, 3 = moderate, and 4 = 
severe). Subjects will be asked to rate the severity of stinging/burning and 
pruritus using a four -point scale (0 = none, 1 = mild, 2 = moderate, and 3 = 
severe) at each visit (Baseline [pre- and post -application], and Weeks 4, 8, 
and 12).  
Product Name: [CONTACT_229808] 17Î±- Propi[INVESTIGATOR_16847] (CB -03-01) Protocol: CB-03-01/25 
Sponsor Name: [CONTACT_229771] S.p.A.  Protocol Date: August 06, 2015 
 
CONFIDENTIAL  Page 8 of 55 
TI SOP 305 -A Protocol Template, Version 06  Study Endpoints  Efficacy  Endpoints:  
Primary Endpoints (Hierarchical)  
â€¢ P1: Proportion of subjects in each treatment group achieving 
â€œsuccessâ€ at Week 12, with â€œsuccessâ€ defined as an IGA score of 
â€œclear (score=0)â€ or â€œalmost clear (score=1)â€ AND at least a two -
point reduction in IGA compared to Baseline.  
â€¢ P2: Absolute change from  Baseline in non -inflammatory lesion 
counts in each treatment group at Week 12.  
â€¢ P3: Absolute change from Baseline in inflammatory lesion counts 
in each treatment group at Week 12.  
 
Secondary Endpoints (Hierarchical)  
â€¢ S1: Absolute change from Baseline in tot al lesions counts in each 
treatment group at Week 12. 
â€¢ S2: Percent change from Baseline in total lesions counts in each 
treatment group at Week 12. 
â€¢ S3: Percent change from Baseline in non -inflammatory lesions 
count in each treatment group at Week 12.  
â€¢ S4: Percent change from Baseline in inflammatory lesions count in 
each treatment group at Week 12.  
 
Safety Endpoints:  
â€¢ Local and systemic AEs at every visit (Baseline, Weeks 4, 8, and 
12). 
â€¢ LSRs: telangiectasia, skin atrophy, striae rubrae, erythema, edema, 
scalin g/dryness, stinging/burning, and pruritus scored by [CONTACT_229774] (Baseline, Weeks 4, 8, and 12).  
â€¢ UPTs in all WOCBP at every visit (Baseline, Weeks 4, 8, and 12).  
â€¢ Material changes from Baseline in ECGs at Week 12.  
Sample Size 
Calculations and Power Considerations  Assumptions used for sample size calculations were estimated from Phase 2 
Dose Escalation Study (171 -7151- 201), using a subset of subjects with 30-
[ADDRESS_276492] to be performed at 
the same significance level Î±=0.[ADDRESS_276493] a null 
hypothesis will imply the failure of rejecting all of the subsequent null hypotheses.  
 
In order to k e e p  t h e  o v e r a l l  Ty p e  I I  e r r o r  Î² = 0 . 1  f o r  t h e  w h o l e  s t u dy ,  t h e 
sample size for the three hypothesis tests on the primary endpoints will be 
calculated considering an individual Type II error Î²=0.033.  
 
For an IGA success rate of (continuity corrected) 14.00% f or CB -03-01 
cream and 2.17% for vehicle cream (odds ratio=7.3), sample size was 
estimated to be 202 subjects per treatment group.  
 
For a mean absolute change from Baseline in non -inflammatory lesion 
counts of -22 for CB -03-01 cream and -1 for vehicle cream  (standard 
deviation=17), sample size was calculated to be [ADDRESS_276494] Name: [CONTACT_229808] 17Î±- Propi[INVESTIGATOR_16847] (CB -03-01) Protocol: CB-03-01/25 
Sponsor Name: [CONTACT_229771] S.p.A.  Protocol Date: August 06, 2015 
 
CONFIDENTIAL  Page 9 of 55 
TI SOP 305 -A Protocol Template, Version 06   
For a mean absolute change from Baseline in inflammatory lesion counts of 
-15 for CB -03-01 cream and -10 for vehicle cream (standard deviation=17), 
sample size was  calculated to be [ADDRESS_276495] for the secondary endpoints will be performed at the 
same significance level Î±=0.05 two -sided of the primary endpoints if and 
only if all the null hypotheses on the primary endpoints are rejected.  
 For a mean absolute change from Baseline in total lesion counts of -35 for 
CB-03-01 cream and -13 for vehicle cream (standard deviation=17), sample 
size was calculated to be 13 subjects per treatment group.  
 For a mean percent change from Baseline in total lesion counts of -35 for 
CB-03-01 cream and -14 for vehicle cream (standard deviation=40), sample 
size was calculated to be 77 subjects per treatment group.  
 For a mean percent change from Baseline in non -inflammatory lesion counts 
of -33 for CB -03-01 cream and -5 for vehicle cream (standard deviation=40), 
sample size was calculated to be 43 subjects per treatment group.  
 
For a mean percent change from Baseline in inflammatory lesion counts of -37 for CB -03-01 cream and -23 for vehicle cre
am (standard 
deviation=40), sample size was calculated to be [ADDRESS_276496] 350 subjects in each treatment group 
(CB-03-01 cream, 1% BID and vehicle BID) will be included into each 
Phase 3 study to p rovide sufficient power (90%) with the chosen primary 
endpoints.  
Statistical Methods  All statistical processing will be performed using SASÂ® unless otherwise 
stated. Summary tables (descriptive statistics and/or frequency tables) will 
be provided for base line variables, efficacy variables, and safety variables.  
Continuous variables will be described by [CONTACT_9086] (n, mean, standard deviation, CV%, minimum, median, and maximum). Frequency 
counts and percentage of subjects within each category are provided for 
categorical data. Summaries will be provided for each treatment group.  
 
Study Sets:  
The Safety set will include all subjects who received at least one application 
of the test article. The intent -to-treat (ITT) set will include all randomize d 
subjects. The per -protocol (PP) set will be a subset of the ITT set and will 
include subjects who completed the study without any significant protocol 
deviations. The analysis of safety will be conducted on the Safety set. The analysis of efficacy will b e conducted on both the ITT and PP sets, with the 
ITT set considered as the primary set for statistical analysis. Multiple 
imputation will be used to impute missing values for the primary endpoints 
and absolute change in total lesions count (S1) in the ITT  analyses. 
Sensitivity analyses will be performed to investigate the robustness of the results obtained on the ITT set for the primary endpoints (change from 
Baseline in non -inflammatory and inflammatory lesion counts and IGA 
Product Name: [CONTACT_229808] 17Î±- Propi[INVESTIGATOR_16847] (CB -03-01) Protocol: CB-03-01/25 
Sponsor Name: [CONTACT_229771] S.p.A.  Protocol Date: August 06, 2015 
 
CONFIDENTIAL  Page 10 of 55 
TI SOP 305 -A Protocol Template, Version 06  â€œsuccessâ€ at Week 12). Missing  values for the other secondary endpoints 
(i.e., S2 -S4: percent change in lesions counts) will be calculated using the 
values obtained from the multiple imputation of the primary efficacy 
endpoints and secondary efficacy endpoint #1 (S1).  
 Efficacy Analyse s: 
Primary Efficacy Analysis  
Hypothesis tests on the primary endpoints will be conducted in hierarchical order for P1 through P3.  
 
P1: A logistic regression model with treatment and analysis center as fixed 
effects will be used to compare the proportion of subjects achieving 
â€œsuccessâ€ in each treatment group at Week 12, where â€œsuccessâ€ is defined as an IGA score of â€œclear (score=0)â€ or â€œalmost clear (score=1)â€ AND at least a two -point improvement in IGA compared to Baseline.  
 P2: An analysis of covariance (ANCOVA) will be used to compare the 
absolute change from Baseline in non -inflammatory lesion counts in each 
treatment group at Week 12, with treatment and analysis center as fixed effects and the Baseline non -inflammatory lesion count as the covariate.  
 
P3: An ANCOVA will be used to compare the absolute change from 
Baseline in inflammatory lesion counts in each treatment group at Week 12 , 
with treatment and analysis center as fixed effects and the Baseline 
inflammatory lesion count as the covariate.  
 
Secondary Efficacy Analysis  
Hypothesis tests on the secondary endpoints will be conducted in 
hierarchical order for S1 through S4.  
 S1: An A NCOVA will be used to compare the absolute change from 
Baseline in total lesion counts in each treatment group at Week 12, with treatment and analysis center as fixed effects and the Baseline total lesion count as the covariate.  
 
S2: An ANCOVA will be used  to compare the percent change from Baseline 
in total lesion counts in each treatment group at Week 12, with treatment and 
analysis center as fixed effects and the Baseline total lesion count as the covariate. 
 
S3: An ANCOVA will be used to compare the percent change from Baseline 
in non -inflammatory lesion counts in each treatment group at Week 12, with 
treatment and analysis center as fixed effects and the Baseline non -
inflammatory lesion count as the covariate.  
 S4: An ANCOVA will be used to compare the percent change from Baseline 
in inflammatory lesion counts in each treatment group at Week 12, with 
treatment and analysis center as fixed effects and the Baseline inflammatory 
lesion count as the covariate.  
 Treatment Compliance and Extent of Exposure Ana lyses:  
Treatment Compliance  
Product Name: [CONTACT_229808] 17Î±- Propi[INVESTIGATOR_16847] (CB -03-01) Protocol: CB-03-01/25 
Sponsor Name: [CONTACT_229771] S.p.A.  Protocol Date: August 06, [ADDRESS_276497] article will be evaluated at each visit and overall 
according to the following formula:  
100 Ã—  ð‘ð‘ð‘ð‘ð‘ð‘ð‘ð‘ð‘ð‘ð‘ð‘  ð‘œð‘œð‘œð‘œ ð‘Žð‘Žð‘Žð‘Žð‘Žð‘Žð‘ð‘ð‘Žð‘Žð‘Žð‘Ž ð‘Žð‘Žð‘Žð‘Žð‘Žð‘Žð‘Žð‘Žð‘Žð‘Žð‘Žð‘Žð‘Žð‘Žð‘Žð‘Žð‘Žð‘Ž ð‘œð‘œð‘Žð‘Žð‘Žð‘Ž
ð‘ð‘ð‘ð‘ð‘ð‘ð‘ð‘ð‘ð‘ð‘ð‘  ð‘œð‘œð‘œð‘œ ð‘Žð‘Žð‘Žð‘Žâ„Žð‘ð‘ð‘’ð‘’ð‘ð‘ð‘Žð‘Žð‘ð‘ð‘’ð‘’ ð‘Žð‘Žð‘Žð‘Žð‘Žð‘Žð‘Žð‘Žð‘Žð‘Ž ð‘Žð‘Žð‘Žð‘Žð‘Žð‘Žð‘Žð‘Žð‘œð‘œð‘Žð‘Žð‘Žð‘Ž 
Non-compliance will be defined as a compliance value less than 80%.  
 
Descriptive statistics will be used to summarize test article compliance at 
each visit and overall for the ITT and PP sets. The proportion of compliant and non -compliant subjects will be summarized by [CONTACT_229775].  Subjects with an overall 
compliance not evaluable (due to missing data) or less than 80% will be excluded from the PP set. 
 
Extent of Exposure  
Descriptive statistics will be used to summarize exposure to test article for the ITT, PP, and Safety sets. The total amount of test article used (grams applied) will be calculated for each subject from the weights of the returned test articles. The mean daily amount of test article applied (total amount of 
test article used/number of days of treatment) will be calculated for each 
subject. 
 
Safety Analyses:  
Local Skin Reactions (LSRs)  
LSRs (telangiectasia, skin atrophy, striae rubrae, erythema, edema, 
scaling/dryness, stinging/burning, and pruritus) will be summarized by [CONTACT_229776].  
 
Adverse Events (AEs)  
Pre-treatment AEs (PTAEs) and Treatment Emergent AEs (TEAEs) will be 
coded using the MedDRA codi ng dictionary. TEAEs will be summarized by 
[CONTACT_6654]. The number and proportion of subjects with any TEAE and the number of TEAEs will be tabulated by [CONTACT_11189] (SOC) and preferred term (PT), seriousness, relationship to t est 
article, and severity.  
 
Electrocardiograms (ECGs ) 
ECGs will be evaluated for any material change during the study period. Results (normal/borderline/abnormal) of the ECG and descriptive statistics will be provided by [CONTACT_229777] h eart rate, RR duration, 
PR duration, QRS duration, QT duration including Bazettâ€™s and Fridericiaâ€™s 
corrections, and P axis for the Safety set. Changes in overall interpretation 
(normal/abnormal/borderline) of the ECG from Baseline to Week [ADDRESS_276498] Name: [CONTACT_229808] 17Î±- Propi[INVESTIGATOR_16847] (CB -03-01) Protocol: CB-03-01/25 
Sponsor Name: [CONTACT_229771] S.p.A.  Protocol Date: August 06, 2015 
 
CONFIDENTIAL  Page 12 of 55 
TI SOP 305 -A Protocol Template, Version 06  SCHEDULE OF EVENTS  
PROCEDURES  Visit 1  
Screening/  
Baseline  
Day 1  Visit 2  
 
Week 4  
(Day 29 Â± 5) Visit 3  
 
Week 8  
(Day 57 Â± 7) Visit 4  
 
Week 121 
(Day 85 Â± 10) 
Informed Consent/Assent2 X2    
Medical/Dermatological History  X    
Demographics  X    
Inclusion/Exclusion Criteria  X    
Dermatologic & Limited Physical  
Exam  X    
Fitzpatrick Skin Type Assessment  X    
Urine Pregnancy Tests3  X X X X 
Electrocardiograms  X   X 
Photographs  X X X X 
Lesion Counts  X X X X 
Investigatorâ€™s Global Assessment  X X X X 
Local Skin Reaction Assessment  X 
(pre- & 
post-
application)  X X X 
Review of Concomitant 
Medications & Procedures  X X X X 
Study Medication and Diary 
Dispensed & Collected4,5 X X X X 
Review of Compliance   X X X 
Adverse Events Evaluation  X X X X 
1. Subjects who terminate early shall complete all final visit activities designated at Week 12.  
2. Consent/assent may be performed up to 45 days prior to the Baseline Visit. Subjects who require â€œwashoutâ€ 
for longer than 45 days will be re-consented.  
3. Testing to be conducted on all WOCBP (see Section 5.1.1  for definition). UPT minimal sensitivity is 
25 mIU/mL.  
4. Instruct subject and t he subjectâ€™s parent/guardian on test article application and provide instruction sheet 
after assessing the subjectâ€™s use of the test article with respect to the amount and number of doses applied 
since the last visit.  
5. Dispense Subject Diary at initial and subsequent visits, as needed.  
Product Name: [CONTACT_229808] 17Î±- Propi[INVESTIGATOR_16847] (CB -03-01) Protocol: CB-03-01/25 
Sponsor Name: [CONTACT_229771] S.p.A.  Protocol Date: August 06, 2015 
 
CONFIDENTIAL  Page 13 of 55 
TI SOP 305 -A Protocol Template, Version 06  ABBREVIATIONS  
AE Adverse Event  
ANCOVA  Analysis of Covariance  
BID Twice a day  
CB-03-01 Cortexolone 17Î± -propi[INVESTIGATOR_229754]%  Percent Coefficient of Variation  
ECG  Electrocardiogram  
EDC  Electronic Data Capture  
FDA  Food and Drug Administration  
GCP  Good Clinical Practices  
HPA  Hypothalamic -Pi[INVESTIGATOR_2117] -Adrenal  
IGA Investigatorâ€™s Global Assessment  
IND Investigational New Drug  
IRB Institutional Review Board  
ITT Intent -to-Treat  
IUD Intrauterine Device  
LSR Local Skin Reaction  
MedDRA  Medical Dictionary for Regulatory Activities  
OTC  Over -the-Counter  
PK Pharmacokinetics  
PP Per-Protocol  
PT Preferred Term  
PTAE  Pre-Treatment Adverse Event  
QA Quality Assurance  
QD Once a day  
RX Prescription  
SAE  Serious Adverse Event  
SAS Statistical Analysis Software  
SOC  System Organ Class  
TEAE  Treatment Emergent Adverse Event  
TI Therapeutics, Incorporated  
UPT  Urine Pregnancy Test  
WOCBP  Women of Childbearing Potential  
Product Name: [CONTACT_229808] 17Î±- Propi[INVESTIGATOR_16847] (CB -03-01) Protocol: CB-03-01/25 
Sponsor Name: [CONTACT_229771] S.p.A.  Protocol Date: August 06, [ADDRESS_276499] Articles and Regimen  ................................................................................ 20  
6.1 Description  ........................................................................................................ 20  
6.2 Instructions for Use and Application ................................................................ 20  
6.3 Warnings, Precautions and Contraindications .................................................. 21  
7. Randomization Assignment .............................................................................. 22  
8. Prior and Concomitant Therapi[INVESTIGATOR_014] ..................................................................... 22  
8.1 Prohibited Medications or Therapi[INVESTIGATOR_014] ................................................................ 22  
8.2 Allowed Medications or Therapi[INVESTIGATOR_014] ................................................................... 23  
9. Study Procedures  .............................................................................................. 24  
9.1 Visit 1 (Day 1): Screening/Baseline  ................................................................. 24  
9.2 Visits 2 (Week 4) and 3 (Week 8) .................................................................... 25  
9.3 Visit 4 (Week 12): End of Study....................................................................... 26  
10. Clinical Evaluations  .......................................................................................... 26  
10.1  Investigatorâ€™s Global Assessment (IGA)  .......................................................... 27  
10.2  Acne Lesion Counting ...................................................................................... 27  
10.3  Fitzpatrick Skin Type Assessment .................................................................... 27  
10.4  Local Skin Reactions (LSRs) ............................................................................ 28  
11. Photography ...................................................................................................... 30  
12. Laboratory Tests  ............................................................................................... 31  
12.1  Urine Pregnancy Tests (UPTs)  ......................................................................... [ADDRESS_276500] Name: [CONTACT_229808] 17Î±- Propi[INVESTIGATOR_16847] (CB -03-01) Protocol: CB-03-01/25 
Sponsor Name: [CONTACT_229771] S.p.A. Protocol Date: August 06, 2015 
CONFIDENTIAL  Page 15 of 55 
TI SOP 305 -A Protocol Template, Version 0613.3  Study Termination  ............................................................................................ 32  
14. Adverse Event Reporting .................................................................................. 32
14.1  Adverse Event (AE)  .......................................................................................... 33  
14.2  Serious Adverse Event (SAE) ........................................................................... 36  
14.3  Pregnancy  .......................................................................................................... 37  
15. Blinding/Unblinding ......................................................................................... [ADDRESS_276501] (IRB) and Informed Consent/Assent .................... 46  
18.3  Protocol Compliance ......................................................................................... 46  
18.4  Protocol Revisions ............................................................................................ 46  
18.5  Study Monitoring .............................................................................................. 47  
18.6  Case Report Form Requirements: Electronic Data Capture (EDC)  .................. [ADDRESS_276502] and Parent/Guardian Instruction sheet ............................. [ADDRESS_276503] Name: [CONTACT_229808] 17Î±- Propi[INVESTIGATOR_16847] (CB -03-01) Protocol: CB-03-01/25 
Sponsor Name: [CONTACT_229771] S.p.A.  Protocol Date: August 06, 2015 
 
CONFIDENTIAL  Page 16 of 55 
TI SOP 305 -A Protocol Template, Version 06  1. BACKGROUND  
CB-03-01 (cortexolone 17Î±-propi[INVESTIGATOR_16865] e) is a steroidal antiandrogen that is being developed 
as a 1% cream for the topi[INVESTIGATOR_112930], an androgen -dependent skin 
disorder. CB -03-[ADDRESS_276504], is a physiological 
component of the pool of endogenous corticosteroids, and is an intermediate in the synthesis of glucocorticoids, but it only exhibits weak glucocorticoid properties [ 1]. 
 In single -dose studies in mouse and in rat, and following repeated subcutaneous 
administration in rats, and dermal administration in rabbits and minipi[INVESTIGATOR_14107], the drug was well tolerated with no significant local or unexpected systemic effects. CB -03-[ADDRESS_276505] been completed with CB-03-01 cream in Europe and the [LOCATION_002], with over 500 subjects exposed to CB -03-01 
creams. All studies were conducted using CB -03-01 cream, 1%; additional concentrations 
of CB -03-01 cream (0.1% and 0.5%) were also used in the most -recent Phase 2 Dose-
Escalating study. The studies included:  
1. A Phase 1 Single Dose Pharmacokinetics (PK) Study in 24 healthy volunteers [randomized, double-blind, vehicle-controlled, single-ascending dose],  
2. A Phase 1 Repeat Dose PK Study in 24 healthy volunteers [randomized, vehicle -
controlled, 14- day repeat -dose], 
3. A Phase 1 Steady State PK Study in 8 subjects with acne vulgaris [single center, open-label, pi[INVESTIGATOR_2268], 6- week repeat -dose] 
4. A Phase 1 Three- week  Cumulative Skin Irritation Study in 36 healthy volunteers, 
5. A Phase 2 Hypothalamic- Pi[INVESTIGATOR_2117] -Adrenal axis (HPA)/PK study in 42 subjects 
with acne vulgaris [open-label, 14- day repeat -dose] 
6. A Phase 2 Comparator Proof of Concept Study in 72 adult subjects wit h facial acne 
vulgaris [randomized, double -blind, vehicle -controlled, active -comparator ( Retin -
A
Â® [tretinoin] 0.05% cream), 8- week repeat -dose], and 
7. A Phase 2 Dose -Escalating Study in 363 subjects with facial acne vulgaris [multi-
center, randomized, double-blind, vehicle controlled, 12- week repeat -dose] 
 Overall, the data that resulted from the completion of the aforementioned studies has demonstrated that CB -03-01 creams selected for clinical development (a) are well tolerated 
locally, (b) result in minimal systemic exposure when applied topi[INVESTIGATOR_897], (c) have a clinical safety profile without any concern and similar to the placebo, and (d) at 1% concentration 
Product Name: [CONTACT_229808] 17Î±- Propi[INVESTIGATOR_16847] (CB -03-01) Protocol: CB-03-01/25 
Sponsor Name: [CONTACT_229771] S.p.A.  Protocol Date: August 06, 2015 
 
CONFIDENTIAL  Page 17 of 55 
TI SOP 305 -A Protocol Template, Version 06  applied BID are significantly more effective than its vehicle at reducing inflammatory and 
non-inflammatory lesions counts in adolescent and adult subjects. 
 
CB-03-01 could offer advantages over existing products for acne vulgaris due to its 
potential efficacy and lack of systemic antiandrogen activity. Because its pharmacological action appears to be limited to the local site of application, use of CB -03-01 may be able 
to mitigate the side effects related to systemic exposure to hormonal agents currently used in the treatment of acne.  
2. RATIONALE  
The concentration of CB -03-01 selected for the initial clinical studies (1%) was based on 
antiandrogenic activity in the hamster flank organ test in which the best effective concentration was 0.8% [ 1]. The results of the Phase 2 Dose Escalation Study demonstrated 
that CB -03-01 cream, 1% applied BID had more favorable results than other treatments 
(0.1% BID, 0.5% BID, and 1% QD) and no material safety issues were noted with any of 
the concentrations of CB -03-01 cream [ 2]. Based on the collective findings of the previous 
Phase 1 and Phase 2 studies, CB -03-01 cream, 1% BID appears to be the best treatment 
candidate to advance for further clinical study and development as a topi[INVESTIGATOR_229755]. Thus, the present Phase 3 study has been designed to determine and compare 
the efficacy of treatment with CB -03-01 cream, 1% and the vehicle cream applied twice 
daily for 12 weeks in subjects with moderate to severe facial acne vulgaris.  
3. OBJECTIVE  
The primary objective of this study is to determine the safe ty and efficacy of CB -03-01 
cream, 1% versus the vehicle cream applied twice daily for 12 weeks in subjects with facial acne vulgaris.  
4. STUDY DESIGN 
This is a multicenter, randomized, double -blind, vehicle -controlled, parallel -group 
comparison study of safe ty and efficacy for CB -03-01 cream, 1% in male and female 
subjects, [ADDRESS_276506] acne vulgaris of the face (which can include the nose) with an Investigatorâ€™s Global Assessment (IGA) score of [ADDRESS_276507] 30 to a maximum of 75 inflammatory lesions (papules, pustules, and nodules), and at least 30 to a maximum of 100 non-inflammatory lesions (open and closed comedones). At least 700 subjects will be enrolled at approximately 38 sites. Subjects will be randomized in a 1:1 ratio to one of two treatment groups:  
 
1. CB-03-01 (cortexolone 17Î±-propi[INVESTIGATOR_16847]) cream, 1% 
2. Vehicle cream  
 
Product Name: [CONTACT_229808] 17Î±- Propi[INVESTIGATOR_16847] (CB -03-01) Protocol: CB-03-01/25 
Sponsor Name: [CONTACT_229771] S.p.A.  Protocol Date: August 06, [ADDRESS_276508] article to the face twice daily for 12 weeks (see 
Section 6). 
 In addition, a separate open- label long -term extension study is planned. Subjects 
completing the treatment -phase of this trial will be offered the  opportunity to participate in 
this follow -on study (CB -03-01/27).  In this open label study, all subjects will apply the 
active medication (cortexolone 17Î±- propi[INVESTIGATOR_229756], 1%) twice daily for up to 9 
additional months of treatment (for a total of up to 12 months; 0 or 3 months in the pi[INVESTIGATOR_61493] 3 trial and an additional 9 months in the open-label long- term extension study).  
5. STUDY POPULATION 
5.[ADDRESS_276509] (UPT) at the Screening/Baseline 
Visit.  
2. Subject has provided written informed consent/assent. A subject under [ADDRESS_276510] provide written informed assent and be accompanied by [CONTACT_85184]/consent  signing. The parent or legal guardian must 
provide informed consent for the subject. If a subject becomes [ADDRESS_276511] has an Investigatorâ€™s Global Assessment (IGA) score of 3 or 4 [0 (clear) to 4 
(severe) scale].  
                                                 
6 Defined as amenorrhea greater than 12 consecutive months.  
7 Hysterectomy, bilateral tubal ligation (at least six (6) months prior to study entry), or bilateral 
oophorectomy.  
8 Highly effective contraception includes a) total abstinence, b) oral, injected, or implanted hormonal methods 
of contraception, c) intraute rine device (IUD), d) partner vasectomy (performed at least six (6) months prior 
to study entry), or e) double barrier methods of contraception [barrier methods include male or female 
condom, diaphragm with spermicidal foam/gel/film/vaginal suppository, ce rvical cap with spermicides, or 
contraceptive sponge].  
9 Women of childbearing potential (WOCBP) include any female who has experienced menarche or is 10 
years of age or older and who has not undergone successful surgical sterilization (hysterectomy, bilat eral 
tubal ligation or bilateral oophorectomy) or is not postmenopausal [defined as amenorrhea >12 consecutive months]. WOCBP taking hormonal therapy for any reason exclusive of the treatment for acne (e.g., as contraception, etc.) must be on the same treatment for at least [ADDRESS_276512] eight (8) weeks prior to the start of the study.  
Product Name: [CONTACT_229808] 17Î±- Propi[INVESTIGATOR_16847] (CB -03-01) Protocol: CB-03-01/25 
Sponsor Name: [CONTACT_229771] S.p.A.  Protocol Date: August 06, [ADDRESS_276513] has facial acne vulgaris, (which can include the nose), with at least 30 to a 
maximum of 75 inflammatory lesions (papules, pustules, and nodules) and 30 to a  
maximum of 100 non-inflammatory lesions (open and closed comedones). 
5. Subject and parent/guardian (if applicable) are willing to comply with study instructions and return to the clinic for required visits. 
6. Subject has used the same type and brand of make -up, other facial products ( exclusive 
of RX/OTC acne cleansers ) and hair products (e.g., shampoo, gel, hair spray, mousse, 
etc.) for at least one (1) month prior to the Baseline Visit and agrees to continue his/her other general skin and hair care products and regimen for the entire study. 
5.1.[ADDRESS_276514] has greater than two (2) facial nodules. 
4. Subject has nodulocystic acne. 
5. Subject has any condition which, in the investigatorâ€™s opi[INVESTIGATOR_1649], would make it unsafe for the subject to participate in this research study.  
6. Subject i s currently enrolled in an investigational drug or device study.  
7. Subject has  received  an investigational drug or has been treated with an investigational 
device within 30 days prior to the initiation of treatment (Baseline).  
8. Subject has facial hair that could interfere with the study assessments in the opi[INVESTIGATOR_13046].  
9. Subject and parent/guardian (if applicable) are unable to communicate or cooperate 
with the investigator due to language problems, poor mental development, or impaired cerebral function.  
10. Subject may be unreliable for the study including subjects who engage in excessive 
alcohol intake or drug abuse, or subjects who are unable to return for scheduled follow -
up visits. 
11. Subject has known hypersensitivity or previous allergic reaction to any of the active or 
inactive components of the test articles (see Section 6.1). 
12. Subject has the need or plans to be exposed to arti ficial tanning devices or excessive 
sunlight during the trial.  
13. Subject has used any of the following topi[INVESTIGATOR_138250]-acne preparations or procedures on 
the face: 
â€¢ Topi[INVESTIGATOR_900] -acne treatments including, but not limited to, over -the- counter (OTC) 
acne cleansers  or treatments, benzoyl peroxide, antibiotics, azelaic acid, sulfa based 
products, corticosteroids and salicylic acid within two (2) weeks of the initiation of treatment.  
â€¢ Retinoids, including tazarotene, adapalene, tretinoin, within four (4) weeks of the 
initiation of treatment.  
â€¢ Light treatments, microdermabrasion, or chemical peels within eight (8) weeks of 
the initiation of treatment.  
Product Name: [CONTACT_229808] 17Î±- Propi[INVESTIGATOR_16847] (CB -03-01) Protocol: CB-03-01/25 
Sponsor Name: [CONTACT_229771] S.p.A.  Protocol Date: August 06, [ADDRESS_276515] has used the following systemic  anti-acne medications:  
â€¢ Corticosteroids (including intramuscular and intralesional  injections) within four (4) 
weeks of the initiation of treatment. Inhaled, intranasal or ocular corticosteroids are 
allowed if use is stable (stable use is defined as dose and frequency unchanged for at least four (4) weeks prior to the initiation of treatment).  
â€¢ Antibiotics within four (4) weeks of the initiation of treatment with the exception of five (5) days or less of antibiotic therapy during this period, BUT with no antibiotics use permitted within one (1) week prior to the initiation of treatment.  
â€¢ Spi[INVESTIGATOR_229751] (8) weeks of the initiation of treatment with the 
exception of five (5) days or less of spi[INVESTIGATOR_229752], BUT with no spi[INVESTIGATOR_229753] (1) week prior to the initiation of treatment.  
â€¢ Retinoid therapy within six (6) months of the initiation of treatment.  
â€¢ Other systemic therapy which may materially affect the subjectâ€™s acne in the opi[INVESTIGATOR_8574]. 
5.1.[ADDRESS_276516] article name:  [CONTACT_206617]-03-01 Cream, 1% 
Active ingredient: Cortexolone 17Î± -propi[INVESTIGATOR_16847] (11- deoxy -hydrocortisone-17Î± -
propi[INVESTIGATOR_16847]). 
Other ingredients: Cetyl alcohol, glycerol monostearate, liquid paraffin, propylene glycol, tocopherol, sodium edetate, polysorbate 80, citric acid, purified water.  
 Placebo name:   [CONTACT_229811]: Cetyl alcohol, glycerol monostearate, liquid paraffin, propylene glycol, tocopherol, sodium edetate, polysorbate 80, citric acid, purified water.  
6.[ADDRESS_276517] visit, the subjects will be instructed to wash their entire face (the area to be 
treated) with mild soap and water and then dry the area gently. The study staff will then 
instruct the subject and parent/guardian (if applicable) on how to dispense the cream, how much of the test article to use, and where to apply the assigned test article. The first application of cream should be applied in the office at Visit [ADDRESS_276518] Name: [CONTACT_229808] 17Î±- Propi[INVESTIGATOR_16847] (CB -03-01) Protocol: CB-03-01/25 
Sponsor Name: [CONTACT_229771] S.p.A.  Protocol Date: August 06, 2015 
 
CONFIDENTIAL  Page 21 of 55 
TI SOP 305 -A Protocol Template, Version 06  will be dispensed onto a fingertip and applied to the face by [CONTACT_229778] (e.g., forehead, nose, cheeks, chin). Using a fingertip, the cream will be spread to provide a thin, uniform layer of the cream over the entire face.  Subjects and parents/guardians (if applicable) will be instructed to apply the cream to the whole face twice daily (morning and in the evening) for [ADDRESS_276519] eight (8) hours between applications. All subjects should not wash the treated area for at least four (4) hours following test article application; and MUST 
NOT  APPLY THE TEST ARTIC LE WITHIN FOUR (4) HOURS PRIOR TO ANY 
STUDY VISIT . 
 Subjects will be provided with a Subject Diary to record the dates and time of application. Subjects will be instructed to only apply the study cream to the face as instructed by [CONTACT_229779]. Note: T he dispensing, recording, and 
application of the test article by [CONTACT_229780]â€™s parent/guardian.  
 Subject and parent/guardian (if applicable) will also be provided with a Subject Instruction Sheet providing them with instructions on how to use and store the cream at home during the study period.  Subject and parent/guardian (if applicable) will be instructed to bring all the containers of cream (used and unused) and their completed diaries to each visit. The study  staff will 
weigh all the returned containers and will record the weights on the appropriate study medication accountability logs and case report forms (CRFs).  
 
Subjects who are not compliant with applying the creams as instructed (determined from subject diaries and/or the weight of test article used) may  be discontinued from the study. 
6.[ADDRESS_276520] Name: [CONTACT_229808] 17Î±- Propi[INVESTIGATOR_16847] (CB -03-01) Protocol: CB-03-01/25 
Sponsor Name: [CONTACT_229771] S.p.A.  Protocol Date: August 06, [ADDRESS_276521] not be pregnant or planning a pregnancy during the study period. 
7. RANDOMIZATION ASSIGNMENT  
Subjects who are eligible for enrollment into the study will be randomized to receive CB -
03-01 cream or vehicle cream in a 1:[ADDRESS_276522] kits will be dispensed according to the kit number 
assigned by [CONTACT_25003]/IWRS system as subjects are enrolled. At each site, the study staff 
will add the site number (provided to each site) and the subject number (starting with 001) to each kit label. The kit number dispensed to each subject will also be recorded on the 
source documents and CRFs. Treatment group designation will remain blinded until the final database is locked (unless unblinding is required as described in Section 15). Subjects 
who withdraw prematurely from the study will not be replaced. 
8. PRIOR AND CONCOMITANT THERAPI[INVESTIGATOR_229757] 30 days prior to the start of the study 
(Screening, Visit 1) will be recorded on the appropriate CRFs with the corresponding indication. The medications to be recorded include RX and OTC medications (except vitamins and dietary supplements not use d to treat a medical condition). All medications 
taken on a regular basis should be recorded on this page prior to commencing the use of the test article.  
 Therapi[INVESTIGATOR_014] (medication and non -medication therapi[INVESTIGATOR_014]) not restricted by [CONTACT_28249]. Vitamins and mineral supplements are permitted at dosages considered by [CONTACT_28250]. Non- prohibited chronic therapi[INVESTIGATOR_229758] 
[ADDRESS_276523] be recorded on the Concomitant Therapy Form. The reason for any change in concomitant therapi[INVESTIGATOR_229759], if appropriate, reported as, or in conjuncti on with, an adverse event . 
8.1 Prohibited Medications or Therapi[INVESTIGATOR_229760]:  
 
Prior to entry  into the study , subjects must not use the medications and/or procedures on 
the face as specified in Section 5.1.2. 
 
During the study , subjects must not use the following products and/or procedures on the 
face:  
 
Product Name: [CONTACT_229808] 17Î±- Propi[INVESTIGATOR_16847] (CB -03-01) Protocol: CB-03-01/25 
Sponsor Name: [CONTACT_229771] S.p.A.  Protocol Date: August 06, 2015 
 
CONFIDENTIAL  Page 23 of 55 
TI SOP 305 -A Protocol Template, Version 06  â€¢ Topi[INVESTIGATOR_900] -acne treatments including, but not limited to, OTC acne cleansers or 
treatments, benzoyl peroxide, antibiotics, azelaic acid, sulfa based products, 
corticosteroids, and salicylic acid. 
â€¢ Retinoids including tazarotene, adapalene, and tretinoin. 
â€¢ Light treatments (including artificial tanning devices), microdermabrasion, or 
chemical peels.  
â€¢ Any other investigational drug or use of any investigational device 
â€¢ Systemic medications with potential anti- acne effects including:  
â€¢ Corticosteroids (including intramuscular and intralesional injections). Inhaled, 
intranasal, or ocular corticosteroids are allowed (see Section 8.2). 
â€¢ Antibiotics  
â€¢ Spi[INVESTIGATOR_8407] 
â€¢ Retinoid thera py 
â€¢ The addition of hormonal contraception 
â€¢ Change to pre-existing hormonal contraception  
â€¢ Other systemic therapy, which may materially affect the subjectâ€™s acne in the opi[INVESTIGATOR_871]. 
 
Other chronic medications being used at the time of Baselin e Visit can be continued at the 
discretion of the investigator. The reason for any changes in such concomitant therapi[INVESTIGATOR_229761], or in conjunction with, an AE. 
8.[ADDRESS_276524] be on a consistent skin care progr am (make- up, moisturizers, soap, 
sunscreen, etc. of their choice, exclusive of RX/OTC acne cleansers) for at least one (1) 
month prior to enrollment. The subjectâ€™s skin care regimen will be reviewed and approved prior to their randomization. This skin care  program should not contain any OTC products 
with significant levels of anti- acne ingredients such as retinol or alpha -hydroxy acids (i.e., 
lactic acid, glycol acid, etc. at greater than 5%).  
 No additional medications, including OTC preparations, should be used without the knowledge and, if possible, permission of the investigator. Vitamins and mineral supplements are permitted at dosages considered by [CONTACT_28250]. The addition, discontinuation, or dose change  of any concomitant 
medications will be documented in the source documents.  Medications will be permitted, at the discretion of the investigator, to treat local skin reactions, if applicable.  
 
Intranasal, inhaled, and ophthalmic steroids used for the management of allergies, 
pulmonary disorders, or other conditions exclusive of acne are NOT considered 
prohibited medications, but should be recorded on the Concomitant Medication Form.  
 
Product Name: [CONTACT_229808] 17Î±- Propi[INVESTIGATOR_16847] (CB -03-01) Protocol: CB-03-01/25 
Sponsor Name: [CONTACT_229771] S.p.A.  Protocol Date: August 06, [ADDRESS_276525] be recorded on the CRFs. The 
reason for any changes in concomitant medications or therapi[INVESTIGATOR_014]/procedures should be reported  and should reflect either a baseline medical condition documented in the medical 
history of the CRF or an AE. 
9. STUDY PROCEDURES  
The study will consist of a Screening/Baseline Visit and three (3) scheduled visits.  
 
Specific activities for each study visit are listed below.  
9.1 Visit 1 (Day 1): Screening/Baseline 
Subjects can be screened for the study up to 45 days before Visit 1. During screening, the study requirements will be reviewed, written informed consent/assent obtained, and eligibility confirmed. If app licable, the washout from prohibited medications or treatments 
will be determined and implemented. Subjects who require â€œwashoutâ€ for longer than 45 days will be re -consented.  
 At Screening, the investigator or designee will:  
â€¢ Obtain a signed, written informed consent (unless the subject signed a consent 
within the past 45 days). Note: a subject under [ADDRESS_276526] provide written 
informed assent and be accompanied by [CONTACT_85184]/consent signing. The parent or legal guardian must provide informed consent for the subject. If a subject becomes [ADDRESS_276527] provide written informed consent at that time to continue study participation.  
â€¢ Complete review and documentation of the subjectâ€™s medical and dermatological 
history and demographic information. 
â€¢ Record any concomitant medications and therapi[INVESTIGATOR_014]. 
â€¢ Confirm the subject meets the inclusion/exclusion criteria.  
â€¢ Have subject complete washout from any prohibited medications, if necessary. 
 
Once the Screening procedures have been completed, the investigator or designee will:  
â€¢ Perform a dermatologic exam and brief physical exam (including vital signs, height, 
and weight). 
â€¢ Perform a Fitzpatrick Skin Type assessment (see Section 10.3).  
â€¢ Perform a UPT for all WOCBP (see Section 5.1.1  for definition). The results must 
be negative for the subject to be enrolled into the study. 
â€¢ Perform an ECG.  
Product Name: [CONTACT_229808] 17Î±- Propi[INVESTIGATOR_16847] (CB -03-01) Protocol: CB-03-01/25 
Sponsor Name: [CONTACT_229771] S.p.A.  Protocol Date: August 06, 2015 
 
CONFIDENTIAL  Page 25 of 55 
TI SOP 305 -A Protocol Template, Version 06  â€¢ Perform IGA (see Section 10.1) and acne lesion counts (see Section 10.2) prior to 
the first application of the test article.  
â€¢ Record Baseline LSRs (prior to application of the test article) (see Section 10.4).  
â€¢ Perform photography for all subjects at all sites (see Section 11). 
â€¢ If the subject meets the inclusion/exclusion criteria, randomize the subject to the 
next available (lowest) subject number.  
â€¢ Weigh and dispense initial tube(s) of test article.  
â€¢ Complete the Study Medication Accountability Log.  
â€¢ Dispense the Subject Instruction Sheet to the subject and parent/guardian (if 
applicable) ( Appendix 1).  
â€¢ Dispense the Subject Diary ( Appendix 2) to the subject and parent/guardian (if 
applicable) and provide completion instructions. 
â€¢ Instruct the subject and parent/guardian (if applicable) where and how to apply the 
initial dose of test article to the acne lesions o n the face following the procedures 
in Section 6.2. The first application should occur in the office under supervision of 
the study staff.  
â€¢ Record any AEs and LSRs (see Section 10.4) after the initial application of the test 
article.  
â€¢ Instruct the subject and parent/guardian (if applicable) to apply the test article 
(about 1 gram) to the whole face twice per day, with at least eight (8) hours between 
applications. 
â€¢ Update the Screening and Enrollment Log.  
â€¢ Schedule Visit 2 (Week 4). 
9.2 Visits 2 (Week 4) and 3 (Week 8) 
The visit windows for Visits 2 and 3 are Day 29 Â± 5 and Day 57 Â± 7, respectively.  At these visits, the investigator or designee will:  
 
â€¢ Observe/query the subject about any changes in his/her health since the previous study visit, including concomitant medications/therapi[INVESTIGATOR_014], and document the 
findings. 
â€¢ Assess any LSRs associated with the subjectâ€™s acne or the topi[INVESTIGATOR_229762] (see Section 10.4).  
â€¢ Initiate/update  the appropriate AE form, if applicable. 
â€¢ Perform a UPT for all WOCBP (see Section 5.1.1 for definition). 
â€¢ Perform photography (see Section 11). 
â€¢ Perform IGA (see Section 10.1) and acne les ion counts (see Section 10.2).  
â€¢ Collect and dispense another (new) Subject Diary, if necessary ( Appendix 2).  
â€¢ Collect and weigh used tubes of test article and weigh/dispense additional tubes, if necessary (see Appendix 3). If subject is under or over utilizing the test article 
remember to re-educate them regarding proper use and application. 
Product Name: [CONTACT_229808] 17Î±- Propi[INVESTIGATOR_16847] (CB -03-01) Protocol: CB-03-01/25 
Sponsor Name: [CONTACT_229771] S.p.A.  Protocol Date: August 06, 2015 
 
CONFIDENTIAL  Page 26 of 55 
TI SOP 305 -A Protocol Template, Version 06  â€¢ Complete the Study Medication Accountability Log.  
â€¢ Review subject ins tructions on the proper application of the test article ( Appendix 
1) with the subject and parent/guardian (if applicable) and the recommended 
amount of test article per application, as well as review and discuss any 
discrepancies or concerns with the subject regarding their use of the diary in 
addition to the amount of test article used since the last visit, if applicable. Subjects 
who have missed multiple applications of the test article may be discontinued from 
the study, at the discretion of the investigator. 
â€¢ Instruct the subject and parent/guardian (if applicable) to continue application of 
the test article (about 1 gram) to the whole face twice per day, with at least eight 
(8) hours between applications. 
â€¢ Schedule the next visit. 
9.3 Visit 4 (Week 12): End of Study  
The visit window for Visit 4 is Day 85 Â± 10. 
 At this visit, the investigator or designee will:  
 
â€¢ Observe/query the subject about any changes in his/her health since the previous 
study visit, including concomitant medications/therapi[INVESTIGATOR_014], and document the 
findings. 
â€¢ Assess any LSRs associated with the subjectâ€™s acne or the topi[INVESTIGATOR_229762] (see Section 10.4).  
â€¢ Initiate/update the appropriate AE form, if applicable.  
â€¢ Perform a UPT for all WOCBP (see Section 5.1.1 for definition). 
â€¢ Perform an ECG.  
â€¢ Perform photography (see Section 11). 
â€¢ Perform IGA (see Section 10.1) and acne lesion counts (see Section 10.2).  
â€¢ Collect the Subject Diary ( Appendix 2).  
â€¢ Collect and weigh used and unused tubes of test articles (see Appendix 3).  
â€¢ Complete the Study Medication Accountability Log.  
â€¢ Complete End of Study Form and discharge subject from the study. 
10. CLINICAL EVALUATIONS  
The following clinical evaluations will be performed according to the schedules indicated 
during the study. The same investigator should complete the evaluations for a given subject 
throughout the study. If this becomes impossible a sub- investigator with overlappi[INVESTIGATOR_229763]. 
Product Name: [CONTACT_229808] 17Î±- Propi[INVESTIGATOR_16847] (CB -03-01) Protocol: CB-03-01/25 
Sponsor Name: [CONTACT_229771] S.p.A.  Protocol Date: August 06, 2015 
 
CONFIDENTIAL  Page 27 of 55 
TI SOP 305 -A Protocol Template, Version 06  10.1 Investigatorâ€™s Global Assessment (IGA)  
At every study visit, overall severity of acne using a five -point scale from 0 = clear to 
4 = severe will be conducted at each visit. This is a static morphological scale that refers 
to a point in time and not a comparison to Baseline. Subjects must have an IGA score of 3 
(moderate) or 4 (severe) at Baseline.  
 
[ADDRESS_276528] Clear  Rare non -inflammatory lesions with no more than one small 
inflammatory lesions.  
2 Mild  Some non -inflammatory lesions with no more than a few 
inflammatory lesions (papules/pustules only; no nodular/cystic 
lesions).  
[ADDRESS_276529] so me 
inflammatory lesions but no more than one nodular/cystic lesion. 
4 Severe  Up to many non -inflammatory lesions and inflammatory lesions 
but no more than a few nodular/cystic lesions. 
10.2 Acne Lesion Counting  
The number of inflammatory lesions (papules, pustules, and nodules) and non-inflammatory lesions (open and closed comedones) on the face vertically from the hairline 
to mandible rim and horizontally from ear to ear, including those on the nose will be 
counted to determine subject eligibility at Visit 1. Subjects must have at least 30 to a maximum of 75 inflammatory lesions and 30 to a maximum of 100 non- inflammatory 
lesions on the face (which can include the nose) at Baseline.  
 Lesions are defined as follow s: 
â€¢ Comedones- open (blackheads) and closed (whiteheads).  
â€¢ Papules - raised inflammatory lesions with no visible purulent material.  
â€¢ Pustules- raised inflammatory lesions with visible purulent material.  
â€¢ Nodules- Any circumscribed, inflammatory masses greater or equal to [ADDRESS_276530]â€™s skin phototype (I -VI) 
using the Fitzpatrick Skin Type Assessment as described below:  
 
Product Name: [CONTACT_229808] 17Î±- Propi[INVESTIGATOR_16847] (CB -03-01) Protocol: CB-03-01/25 
Sponsor Name: [CONTACT_229771] S.p.A.  Protocol Date: August 06, 2015 
 
CONFIDENTIAL  Page 28 of 55 
TI SOP 305 -A Protocol Template, Version 06  FITZPATRICK SKIN TYPE  
Skin 
Phototype  Typi[INVESTIGATOR_96218]  
I Pale white skin, blue/hazel eyes, 
blond/red hair  Always burns, does not tan 
II Fair skin, blue eyes  Burns easily, tans poorly  
III Darker white skin  Tans after initial burn  
IV Light brown skin  Burns minimally, tans easily  
V Brown skin  Rarely burns, tans darkly easily  
VI Dark brown or black skin  Never burns, always tans darkly  
10.4 Local Skin Reactions (LSRs)  
At every study visit, the investigator or designee will document the severity of the 
following LSRs known to be associated with application of topi[INVESTIGATOR_8826]: 
â€¢ Telangiectasia  
â€¢ Skin atrophy 
â€¢ Striae rubrae  
A five -point ordinal scale will be used to assess the severity of these reactions (0 = none, 
1 = trace, 2 = mild, 3 = moderate, and 4 = severe).  
 
In addition, the investigator or designee will evaluate the severity of the following LSRs known to be associated with acne vulgaris, using the five -point ordinal scales described 
below: 
â€¢ Erythema  
â€¢ Edema  
â€¢ Scaling/dryness  
 
Product Name: [CONTACT_229808] 17Î±- Propi[INVESTIGATOR_16847] (CB -03-01) Protocol: CB-03-01/25 
Sponsor Name: [CONTACT_229771] S.p.A.  Protocol Date: August 06, 2015 
 
CONFIDENTIAL  Page 29 of 55 
TI SOP 305 -A Protocol Template, Version 06  Erythema : 
0 None  
1 Minimal â€“ barely perceptible erythema  
2 Mild â€“ predominantly minimal erythema (pi[INVESTIGATOR_8745]) in the treated area with or without 
a few isolated areas of more intense erythema  
3 Moderate â€“ predominantly moderate erythema (red) in the treated area with  or 
without a few isolated areas of intense erythema (bright red)  
4 Severe â€“ predominantly intense erythema (bright red) in the treated area with or 
without a few isolated areas of very intense (fiery red) erythema  
 
Edema:  
0 None  
1 Minimal â€“ scant, rare  edema  
2 Mild â€“ easily seen edema, minimally palpable, involving up to 1/3 of the 
Treatment Area  
3 Moderate â€“ easily seen edema and typi[INVESTIGATOR_229764], involving between 1/3 to 
2/3 of the Treatment Area  
4 Severe â€“ easily seen edema, indurated in some ar eas, involving over 2/3 of the 
Treatment Area  
 Scaling/dryness:  
0 None  
1 Minimal â€“ barely perceptible desquamation  
2 Mild - limited areas of fine desquamation in up to 1/3 of the treatment area  
3 Moderate â€“ fine desquamation involving 1/3 to 2/3 of the  treatment area or limited 
areas of coarser scaling  
4 Severe â€“ coarser scaling involving more than 2/[ADDRESS_276531] visit, using the four -point ordinal scales described below:  
â€¢ Stinging/burning 
â€¢ Pruritus  
 
Product Name: [CONTACT_229808] 17Î±- Propi[INVESTIGATOR_16847] (CB -03-01) Protocol: CB-03-01/25 
Sponsor Name: [CONTACT_229771] S.p.A.  Protocol Date: August 06, 2015 
 
CONFIDENTIAL  Page 30 of 55 
TI SOP 305 -A Protocol Template, Version 06  Stinging/burning: 
0 None  
1 Minimal, barely perceptible â€“ tolerable and little discomfort  
2 Moderate â€“ tolerable, but causes some discomfort  
3 Severe â€“ very uncomfortable or intolerable  
 
Pruritus (itching):  
0 None - no evidence of itching  
1 Mild - only aware of itching at times, only present when relaxing, not present when 
focused on other activities  
2 Moderate - often aware  of itching, annoying, sometimes disturbs sleep and daytime 
activities  
3 Severe -constant itching, distressing; frequent sleep disturbance, interferes with 
activities  
 These LSRs will be collected independently of AEs. Only LSRs that require medical intervention (e.g., prescription medication) or require withholding the application of the test articles will be documented as AEs. Any LSRs that are not listed above will be recorded as AEs.  
11. PHOTOGRAPHY  
Photography documentation is required in this study. Photographs taken as part of this 
study will be used to document the effects of treatment, AEs, or other findings during the trial. Color photographs (both sides of the face and the front of the face) of the areas with 
acne lesions of all enrolled subject s will be performed at the Baseline Visit prior to 
application of the test articles and at Visits 2, 3, and 4. The study sites will be provided with suggested guidelines to assist them in taking standardized photographs. In addition, investigators at all s tudy sites may take photos as they deem appropriate to document the 
clinical status of the subject (e.g., an AE, etc.).  Photographs taken for this study are for 
informational purposes only and are not to assist in grading or for any other assessment.  Note: Subjects may decline to have photographs taken during the conduct of the study. If a subject initially consents to photographs, then declines further photography, the Sponsor may use the photographs taken under consent for the purposes noted above. 
Product Name: [CONTACT_229808] 17Î±- Propi[INVESTIGATOR_16847] (CB -03-01) Protocol: CB-03-01/25 
Sponsor Name: [CONTACT_229771] S.p.A.  Protocol Date: August 06, 2015 
 
CONFIDENTIAL  Page 31 of 55 
TI SOP 305 -A Protocol Template, Version 06  12. LABORATORY TESTS  
12.1 Urine Pregnancy Tests (UPTs)  
The UPT will be performed at the study site if the site is registered and conforms to Clinical 
Laboratory Improvement Amendments  (CLIA) regulations for such testing (site possesses 
at a minimum a current valid C LIA Certificate of Waiver) or at an appropriately registered 
reference laboratory. A UPT will be performed at every visit on all WOCBP (see Section 
5.1.1 for definition). The investigator will report the UPT results on the CRFs, in the 
subjectâ€™s medical records and, if applicable, in independent records maintained at the study 
site. The UPT used must have a minimum sensitivity of 25 mIU of Î²-HCG/mL o f urine.  
13. END OF STUDY CRITERI A 
At the end of each subjectâ€™s participation in the study, the investigator will complete an 
End of Study form for all completed and discontinued subjects. 
13.[ADDRESS_276532] may be withdrawn from the study prior to completion for any of the following 
reasons:  
â€¢ Whenever the subject or the subjectâ€™s parent/guardian decides it is in the subjectâ€™s 
best interest to be withdrawn, Note: if the subject or parent/guardian decides to withdraw from the study due to an AE then it should be classified as withdrawal due to an AE. 
â€¢ Whenever the investigator decides it is in the subjectâ€™s best interest to be withdrawn  
â€¢ AEs 
â€¢ Worsening of condition or treatment failure (in the opi[INVESTIGATOR_871]) 
â€¢ Noncompliance 
â€¢ Pregnancy  
â€¢ Lost to follow-up  
â€¢ Sponsor administrative reasons 
 If a subject withdraws prematurely during the 12- week treatment period for any reason, the 
Visit [ADDRESS_276533] is withdrawn from the study for a treatment -related 
AE (i.e., possibly, probably or definitely related as defined in Section 14), when possible, 
the subject should be followed until resolution or stabilization of the AE. 
Product Name: [CONTACT_229808] 17Î±- Propi[INVESTIGATOR_16847] (CB -03-01) Protocol: CB-03-01/25 
Sponsor Name: [CONTACT_229771] S.p.A.  Protocol Date: August 06, [ADDRESS_276534] that it may be unwise to 
continue, he or she may stop the study. A study termination by [CONTACT_122723]. 
 In addition, a written statement fully documenting the reasons for this action will be submitted to the Sponsor by [CONTACT_229781] (5) working days.  In the event that the Sponsor chooses to discontinue or terminate the study, appropriate notification will be given to the investigator.  
14. ADVERSE EVENT REPORT ING  
An adverse event  (AE) is any untoward medical occurrence associated with the use of a 
drug in humans, whether or not considered drug related. 
 
 
An AE (also referred to as an adverse experience) can be any unfavorable and unintended 
sign (e.g., an abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, without any judgment about causality. An AE can arise from any use of the drug  (e.g., off -label use, use in combination with any drug) and from any route of 
administration, formulation, or dose, including an overdose.  
Information on the medical condition of subjects should begin following the subjectâ€™s written consent/assent to participate in the study and a medical history should be taken at screening. During any wash out and baseline periods, any changes in the health of subjects should be recorded as changes in medical history unless the event occurred as a result of a study- related procedure and is unanticipated, in such cases, the event should be recorded 
as an AE and reported to the Institutional Review Board (IRB) as an â€œunanticipated problemâ€ in accordance with local procedures. Other changes in subject health information becomes AE data when the subject begins dosing with the test article and therefore AE data should be collected from the date of the first dose of test article. These data are considered treatment -emergent AEs.  
 Timely and complete reporting of all AEs assists Therapeutics, Inc. (TI) in identifying any untoward medical occurrence, thereby [CONTACT_17155]:  
1) protection of the safety of study subjects;  
2) a greater understanding of the overall safety profile of the test article;  
3) recognition of dose- related test article toxicity;  
4) appropriate modification of study protocols;  
5) improvements in study design or procedures; and  
6) adherence to worldwide regulatory requirements.  
 
Product Name: [CONTACT_229808] 17Î±- Propi[INVESTIGATOR_16847] (CB -03-01) Protocol: CB-03-01/25 
Sponsor Name: [CONTACT_229771] S.p.A.  Protocol Date: August 06, [ADDRESS_276535] article is defined as a pharmaceutical form of an active ingredient or vehicle/placebo 
being tes ted or used as a reference in the study, whether blinded or unblinded. AEs may be 
either spontaneously reported or elicited during questioning and examination of a subject. All AEs must be completely recorded on the AE CRF. If known, the investigator shoul d 
report the diagnosis of the underlying illness or disorder, rather than its individual symptoms. Subjects experiencing AEs that cause interruption or discontinuation of test article, or those experiencing AEs that are present at the end of their particip ation in the 
study should receive follow -up as appropriate. If possible, report the outcome of any AE 
that caused permanent discontinuation or that was present at the end of the study particularly if the AE is considered by [CONTACT_47747]- related (i.e., 
definitely, probably, or possibly related to test article). 
14.1 Adverse Event (AE)  
All AEs must be recorded on the AE CRF. AEs should be followed to resolution or 
stabilization (if possible), and reported as serious adverse events (SAEs) if they become serious.  LSRs that have been reported in subjects treated with CB -03-01 creams (0.1% -1% 
concentration) include (with decreasing frequency) erythema, pruritus, scaling/dryness, skin atrophy, striae rubrae, stinging/burning, edema, and telangiectasia; however most LSRs were typi[INVESTIGATOR_229765]. No subjects discontinued treatment due to these LSRs.  
 AEs that have been reported in subjects treated with CB -03-01 creams (0.1 -1% 
concentration) were minimal, typi[INVESTIGATOR_229766], a nd most were recovered/resolved 
without sequelae at the end of the study. Only two AEs in one (1) subject were judged as probably or possibly related to treatment; both of these treatment -related AEs (burning and 
cold at application site) were mild in seve rity. Two SAEs have been reported to date; both 
were not related to treatment and were resolved at the end of the study. In addition, one subject discontinued early from the study due to an AE (urinary tract infection), which was not related to treatment.  
 The investigator will instruct the subject to report any AEs that may occur during the study. At each visit, the investigator should ask the subject, in non- directive fashion, about any 
change in the subjectâ€™s overall condition since the previous visit.  The severity of each AE, as judged by [CONTACT_093], will be recorded on the appropriate AE CRF and will be graded according to the following scale:  
Mild - The AE is transient and easily tolerated by [CONTACT_423].  
 
Moderate - The AE causes the subject d iscomfort and interrupts the subject's usual 
activities.  
Product Name: [CONTACT_229808] 17Î±- Propi[INVESTIGATOR_16847] (CB -03-01) Protocol: CB-03-01/25 
Sponsor Name: [CONTACT_229771] S.p.A.  Protocol Date: August 06, [ADDRESS_276536]â€™s usual 
activities, and may be incapacitating or life -threatening. 
 
The investigator must determine the relationship of the AE to the test article according to 
the following categories:  
Definite  - An event that follows a reasonable temporal sequence from 
administration of the test article; that follows a known or expected response pattern to the test article; and that is confirmed b y improvement on stoppi[INVESTIGATOR_28214], and reappearance of the event on repeated exposure (re- challenge).  
 
Probable  - An event that follows a reasonable temporal sequence from 
administration of the test article; that follows a known or expected response pattern 
to the test article; and that is confirmed by [CONTACT_3895][INVESTIGATOR_229767]; and that is unlikely to have been caused by [CONTACT_28260]/underlying illness or other drugs, procedures, or other causes. 
 
Possi ble - An event that follows a reasonable temporal sequence from 
administration of the test article; that follows a known or expected response pattern to the test article; but may have been caused by [CONTACT_28260]/underlying illness, other drug, procedure, or other causes.  
 
Unlikely  - An event that does not follow a reasonable temporal sequence from 
administration of the test article; that does not follow a known or expected response pattern to the test article, or most likely was caused by [CONTACT_28260]/underlyin g 
illness, other drug, procedure, or other causes, because of their known effects.  
 
Not Related  - An event almost certainly caused by [CONTACT_28260]/underlying illness, 
other drug, procedure, or other causes.  
The investigator should categorize the outcome of  the AE according to the following 
categories:  
  Fatal - Termination of life as a result of an AE.  
  Not Recovered/Not Resolved - AE has not improved or the subject has not 
recuperated.  
  Recovered/Resolved - AE has improved or the subject has recuperated.  
  Recovered/Resolved with Sequelae - subject recuperated but retained the 
pathological conditions resulting from the prior disease or injury.  
 
Product Name: [CONTACT_229808] 17Î±- Propi[INVESTIGATOR_16847] (CB -03-01) Protocol: CB-03-01/25 
Sponsor Name: [CONTACT_229771] S.p.A.  Protocol Date: August 06, 2015 
 
CONFIDENTIAL  Page 35 of 55 
TI SOP 305 -A Protocol Template, Version 06   Recovering/Resolving -  AE is improving or the subject is recuperating.  
 
 Unknown - Not known, not observed, not recorded or subject refused. 
 The investigator should report the action taken with the test article due to the AE according to the following categories:  
Dose Not Changed  - An indication that a medication schedule was maintained.  
 Dose Increased  - An indication that a medication schedule was modified by 
[CONTACT_60267]; either by [CONTACT_60268], strength or amount.  Dose Reduced  - An indication that a medication schedule was modified by 
[CONTACT_58413], either by [CONTACT_60268], strength or amount.  Drug Interrupted  - An indication that a medication schedule was modified by 
[CONTACT_229782] a prescribed regimen of medication.  
 Drug Withdrawn  - An indication that  a medication schedule was modified through 
termination of a prescribed regimen of medication.  
 Not Applicable  - Determination of a value is not relevant in the current context. 
 Unknown - Not known, not observed, not recorded, or refused. 
 The investigator should report any other action taken due to the AE.  An adverse reaction  is any AE caused by a drug. Adverse reactions are a subset of all 
suspected adverse reactions for which there is reason to conclude that the drug caused the event. For the purposes of prescription drug labeling, the term adverse reaction means an undesirable effect, reasonably associated with the use of a drug that may occur as part of its pharmacological action or may be unpredictable in its occurrence.  
 A suspected adverse reactio n is any AE for which there is a reasonable possibility that 
the drug caused the event.   For the purposes of IND safety reporting, â€œreasonable possibilityâ€ means there is evidence to suggest a causal relationship between the drug and the AE. A suspected a dverse reaction 
implies a lesser degree of certainty about causality than adverse reaction, which means any AE caused by a drug.  
 An AE or suspected adverse reaction is considered â€œunexpectedâ€ if it is not listed in the investigator brochure or is not lis ted at the specificity or severity that has been observed; 
or, if an investigator brochure is not required or available, is not consistent with the risk 
Product Name: [CONTACT_229808] 17Î±- Propi[INVESTIGATOR_16847] (CB -03-01) Protocol: CB-03-01/25 
Sponsor Name: [CONTACT_229771] S.p.A.  Protocol Date: August 06, 2015 
 
CONFIDENTIAL  Page 36 of 55 
TI SOP 305 -A Protocol Template, Version 06  information described in the general investigational plan or elsewhere in the current 
application. For example, under this definition, hepatic necrosis would be unexpected (by [CONTACT_14213]) if the investigator brochure referred only to elevated hepatic enzymes or hepatitis. Similarly, cerebral thromboembolism and cerebral vasculitis would be unexpected (by [CONTACT_14214]) if the investigator brochure listed only cerebral vascular accidents. "Unexpected," as used in this definition, also refers to AEs or suspected adverse reactions that are mentioned in the investigator brochure as occurring with a class of drugs or as anticipated from the pharmacological properties of the drug, but are not specifically mentioned as occurring with the particular drug under investigation. 
14.2 Serious Adverse Event (SAE)  
An event that is serious must be recorded on the AE CRF and on the TI SAE Report Form, 
and requires expeditious handling to comply with regulatory requirements.  An AE or suspected adverse reaction is considered â€œseriousâ€ if, in the opi[INVESTIGATOR_28216], it results in any of the following outcomes: 
â€¢ Death.  
â€¢ Life-threatening event.  
â€¢ Inpatient hospi[INVESTIGATOR_1081]. 
â€¢ Persistent or significant incapacity or substantial disruption of the ability to conduct 
normal life functions. 
â€¢ Congenital anomaly/birth defect.  
â€¢ Is an important medical event - defined as a medical event(s) that may not result in 
death, be life -threatening, or require hospi[INVESTIGATOR_313], based upon appropriate 
medical judgment, may jeopardize the patient/subject and may require medical or 
surgical intervention to prevent one of the outcomes listed in the definition above. 
Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convuls ions that do not result in inpatient hospi[INVESTIGATOR_059], or the development of 
drug dependency or drug abuse. 
 Events NOT considered to be SAEs are: 
â€¢ Hospi[INVESTIGATOR_28217], which was elective or pre -planned, of a pre -
existing condition that did not worsen, and 
â€¢ Treatment on an emergency, outpatient basis, for an event not fulfilling any of the 
definitions of â€œseriousâ€ given above and not resulting in hospi[INVESTIGATOR_063]. 
 
AEs classified as â€œseriousâ€ by [CONTACT_229783]. All serious AEs, 
whether related or unrelated to test article, must be immediately reported by [CONTACT_28262], in the event that he/she is unavailable, to  the 
Project Manager listed on the first page of the protocol.  Written notification of all SAEs 
should be sent to the Project Manager by [CONTACT_28263]. These 
Product Name: [CONTACT_229808] 17Î±- Propi[INVESTIGATOR_16847] (CB -03-01) Protocol: CB-03-01/25 
Sponsor Name: [CONTACT_229771] S.p.A.  Protocol Date: August 06, [ADDRESS_276537] include an 
assessment of whether there is a reasonable possibility that the drug caused the event.  
 
Study endpoints that are SAEs (e.g., all -cause mortality) must be reported in accordance 
with the protocol unless there is evidence suggesting a causal relationship between the drug and the event (e.g., death from anaphylaxis). In this case, the investigator must immediately report the event to the Sponsor. In addition, such information should also be provided to the siteâ€™s respective IRB per their gov erning guidelines for SAE reporting.  
 If only limited information is initially available, follow -up reports are required. Should the 
investigator become aware of an SAE (regardless of its relationship to test article) that occurs within [ADDRESS_276538] be reported in accordance with procedures specified in this protocol. In the event of death, if an autopsy is performed, a copy of the report should be sent to TI, if available.  As required, TI will notify participating  investigators of all suspected adverse reactions 
that are serious and unexpected. This notification will be in the form of an IND safety report of potential serious risks as soon as possible but no later than 15 calendar days after the Sponsor determines that the information is â€œreportableâ€ according to the criteria listed 
in 21 CFR Section 312.32. These are:  
i) Serious and unexpected suspected adverse reactions,  
ii) Findings from other studies including epi[INVESTIGATOR_9037], pooled analyses, or other clinical studies that suggest a significant risk in humans 
exposed to the test articles,  
iii) Findings from animal or in vitro tests that suggest a significant risk to humans exposed to the test articles or reports of significant organ toxicity at or near the expected human exposure, and 
iv) Clinically important increases in the rate of occurrence of serious suspected adverse reactions.  
 Upon receiving such notices, the investigator must review and retain the notice with the Investigator Brochure and immediately su bmit a copy of this information to the responsible 
IRB according to local regulations. The investigator and IRB will determine if the informed consent/assent requires revision. The investigator should also comply with the IRB procedures for reporting any other safety information. Where required, submission of safety updates by [CONTACT_428].  
14.3 Pregnancy  
WOCBP (see Section 5.1.1 for definition) must have a negative UPT prior to study 
enrollment and must use a highly effective method of birth control during the course of the study, in a manner such that risk of failure is minimized. Prior to study enrollment, 
Product Name: [CONTACT_229808] 17Î±- Propi[INVESTIGATOR_16847] (CB -03-01) Protocol: CB-03-01/25 
Sponsor Name: [CONTACT_229771] S.p.A.  Protocol Date: August 06, [ADDRESS_276539] and parent/guardian must sign an informed consent/assent form documenting this discussion. 
 
During the study, all WOCBP should be instructed to contact [CONTACT_229784] (e.g., missed or late menstrual period).  
 WOCBP enrolling into the study must have a pregnancy test prior to study therapy, and monthly throughout the course of the study. The study therapy must be withheld until the results of laboratory pregnancy testing are known, and a negative UPT must be confirmed to continue in the trial. If pregnancy is confirmed during screening, the subject must not receive test article and must not be enrolled in the study.  
 If a subject or investigator suspects that a subject may be pregnant at any time during the study, the test article must be withheld until the results of la boratory pregnancy testing are 
available. If pregnancy is confirmed, the subject must not apply further test article and must be discontinued from the study.  If following initiation of study treatment, it is subsequently discovered that a trial subject was pregnant or may have been pregnant at the time of test article exposure, the investigator 
must immediately notify the Medical Monitor of this event, and record the pregnancy on the appropriate pregnancy surveillance form. The form will be sent to TI. The  investigator 
must notify the IRB of any pregnancy associated with the study therapy and keep careful source documentation of the event.  Protocol- required procedures for those subjects that are discontinued from the study must 
be performed on the subject unless contraindicated by [CONTACT_8663] (e.g., x -ray studies).  
Other appropriate pregnancy follow -up procedures should be considered if indicated, 
including counseling of the subject by [CONTACT_28266] (e.g. , obstetrician). In addition, the investigator must report to TI, on 
the appropriate TI pregnancy surveillance form(s), any follow -up information regarding 
the course of the pregnancy, including perinatal and neonatal outcome. Although pregnancy itself is not an AE, any complications during pregnancy should be recorded as 
AEs (or SAEs, if they fulfill the SAE criteria). Abortion, whether accidental, therapeutic, or spontaneous should be reported as an SAE. Offspring should be followed for a minimum of eight  weeks. Any congenital anomaly/birth defect in a child born to a subject exposed 
to the test article(s) should be recorded as an SAE and details documented in the pregnancy surveillance form.  
15. BLINDING/UNBLINDING  
Blinding is important for the integrity of this clinical drug trial. However, the blind may be broken in the event of a medical emergency in a subject, in which knowledge of the test article identity is critical to the subjectâ€™s management. Before breaking the blind for a 
Product Name: [CONTACT_229808] 17Î±- Propi[INVESTIGATOR_16847] (CB -03-01) Protocol: CB-03-01/25 
Sponsor Name: [CONTACT_229771] S.p.A.  Protocol Date: August 06, [ADDRESS_276540], the investigator s hould determine that the information is necessary (i.e., that it will 
alter the subjectâ€™s immediate management). In many cases, particularly when the 
emergency is clearly not test article related, the problem may be effectively managed by [CONTACT_229785]. The 
need to break the blind should first be discussed with the responsible Medical Monitor and the best method to do this will be determined. 
16. CLINICAL SUPPLIES  
16.[ADDRESS_276541] articles will be packaged and labeled by [CONTACT_16015]. Detailed information 
on the packaging/labeling, blinding/unblinding, storage and preparation, dispensing, 
accountability etc. is included in Ap pendix 3. 
16.2 Supplies Provided by [CONTACT_229786]  
â€¢ CRFs  
â€¢ Source document draft templates 
â€¢ Site regulatory binder or document filing system  
â€¢ UPT kits  
â€¢ Weighing scales (if necessary)  
â€¢ High quality digital camera and any associated software (if needed)  
16.3 Supplies Provided by [CONTACT_10670] 
â€¢ Urine collection containers for UPTs 
â€¢ Computer to store and view photographs of subjects 
17. STATISTICAL CONSIDERATIONS  
17.1 Study Endpoints  
17.1.1  Efficacy Endpoints 
Primary Endpoints (Hierarchical):  
â€¢ P1: Proportion of subjects in each treatment group achievin g â€œsuccessâ€ at Week 
12, with â€œsuccessâ€ defined as an IGA score of â€œclear (score=0)â€ or â€œalmost clear (score=1)â€ AND at least a two -point reduction in IGA compared to Baseline. 
â€¢ P2: Absolute change from Baseline in non- inflammatory lesion counts in each 
treatment group at Week 12. 
â€¢ P3: Absolute change from Baseline in inflammatory lesion counts in each treatment 
group at Week 12. 
 
Product Name: [CONTACT_229808] 17Î±- Propi[INVESTIGATOR_16847] (CB -03-01) Protocol: CB-03-01/25 
Sponsor Name: [CONTACT_229771] S.p.A.  Protocol Date: August 06, 2015 
 
CONFIDENTIAL  Page 40 of 55 
TI SOP 305 -A Protocol Template, Version 06  Secondary Endpoints (Hierarchical): 
â€¢ S1: Absolute change from Baseline in total lesion counts (including inflammatory 
and non- inflammatory) in each treatment group at Week 12.  
â€¢ S2: Percent change from Baseline in total lesion counts (including inflammatory 
and non- inflammatory) in each treatment group at Week 12.  
â€¢ S3: Percent change from Baseline in non -inflammatory lesions count in each  
treatment group at Week 12. 
â€¢ S4: Percent change from Baseline in inflammatory lesions count in each treatment 
group at Week 12. 
17.1.2  Safety Endpoints  
â€¢ Local and systemic AEs at every visit (Baseline, Weeks 4, 8, and 12). 
â€¢ LSRs: telangiectasia, skin atrophy, striae rubrae, erythema, edema, scaling/dryness, 
stinging/burning, and pruritus scored by [CONTACT_229787] 
(Baseline, Weeks 4, 8, and 12). 
â€¢ UPTs in all WOCBP at every visit (Baseline, Weeks 4, 8, and 12). 
â€¢ Material changes from Baseline in ECGs at Week 12.  
17.2 Sample Size Calculations and Power Considerations  
Assumptions used for sample size calculation were estimated from Phase 2 Dose Escalation Study (171 -7151- 201) [ 2], using a subset of subjects with 30- [ADDRESS_276542] to be performed at the same significance level Î±=0.[ADDRESS_276543] a null hypothesis will imply 
the failure of rejecting all of the subsequent null hypotheses.  In order  to keep the overall Type II error Î²=0.1 for the whole study, the sample size for the 
three hypothesis tests on the primary endpoints will be calculated considering an individual Type II error Î²=0.033.  
 For an IGA success rate of (continuity corrected) 14.00% for CB -03-01 cream and 2.17% 
for vehicle cream (odds ratio=7), sample size was estimated to be 202 subjects per treatment group.  
 For a mean absolute change from Baseline in non- inflammatory lesion counts of -22 for 
CB-03-01 cream and -1 for vehicle cr eam (standard deviation=17), sample size was 
calculated to be [ADDRESS_276544] Name: [CONTACT_229808] 17Î±- Propi[INVESTIGATOR_16847] (CB -03-01) Protocol: CB-03-01/25 
Sponsor Name: [CONTACT_229771] S.p.A.  Protocol Date: August 06, 2015 
 
CONFIDENTIAL  Page 41 of 55 
TI SOP 305 -A Protocol Template, Version 06  For a mean absolute change from Baseline in inflammatory lesion counts of -14 for CB -
03-01 cream and -11 for vehicle cream (standard deviation=17), sample size was calculated 
to be [ADDRESS_276545] for the secondary endpoints will be performed at the same significance level Î±=0.05 two -sided of the primary endpoints if and only if all the null hypotheses on 
the primary endpoints are rejected.  
 For a mean absolute change from Baseline in total lesion counts of -35 for CB -03-01 cream 
and - 13 for vehicle cream (standard deviation=17), sample size was calculated to be 13 
subjects per treatment group.  For a mean percent change from  Baseline in total lesion counts of -35 for CB -03-01 cream 
and - 14 for vehicle cream (standard deviation=40), sample size was calculated to be 77 
subjects per treatment group.  For a mean percent change from Baseline in non -inflammatory lesion counts of -33 for 
CB-03-01 cream and -5 for vehicle cream (standard deviation=40), sample size was 
calculated to be 43 subjects per treatment group.  For a mean percent change from Baseline in inflammatory lesion counts of -37 for CB -03-
01 cream and -23 for vehicle cream (standard deviation=40), sample size was calculated to 
be [ADDRESS_276546] 350 subjects in each treatment group (CB -03-01 
cream, 1% BID and vehicle BID) will be included in each Phase 3 study to pr ovide 
sufficient power (90%) with the chosen primary endpoints. 
17.3 Statistical Methods  
All statistical processing will be performed using SAS
Â® unless otherwise stated. Summary 
tables (descriptive statistics and/or frequency tables) will be provided for baseline 
variables, efficacy variables, and safety variables. Continuous variables will be described by [CONTACT_9086] (n, mean, standard  deviation, CV%, minimum, median, and 
maximum). Frequency counts and percentage of subjects within each category are provided for categorical data. Summaries will be provided for each treatment group.  
 The Safety set will include all subjects who received at least one application of the test article. The ITT set will include all randomized subjects. The PP set will be a subset of the ITT set and will include subjects who completed the study without any significant protocol deviations. The analysis of safety  will be conducted on the Safety set. The analysis of 
efficacy will be conducted on both the ITT and PP sets, with the ITT set considered as the primary set for statistical analysis. Multiple imputation will be used to impute missing values for the primary  endpoints and absolute change in total lesions count (S1) in the ITT 
Product Name: [CONTACT_229808] 17Î±- Propi[INVESTIGATOR_16847] (CB -03-01) Protocol: CB-03-01/25 
Sponsor Name: [CONTACT_229771] S.p.A.  Protocol Date: August 06, 2015 
 
CONFIDENTIAL  Page 42 of 55 
TI SOP 305 -A Protocol Template, Version 06  analyses. Sensitivity analyses will be performed to investigate the robustness of the results 
obtained on the ITT set for the primary endpoints (change from Baseline in non-inflammatory and inflammatory lesion counts and IGA â€œsuccessâ€ at Week 12). Missing 
values for the other secondary endpoints (i.e., S2- S4: percent change in lesions counts) will 
be calculated using the values obtained from the multiple imputation of the primary efficacy  endpoints and secondary efficacy endpoint #1 (S1). 
17.3.1  Efficacy Analyses 
[IP_ADDRESS] Primary Efficacy Analysis  
Hypothesis tests on the primary endpoints will be conducted in hierarchical order for P1 through P3.  P1: A logistic regression model with treatment and analysis center as fixed effects will be 
used to compare the proportion of subjects achieving â€œsuccessâ€ in each treatment group at Week 12, where â€œsuccessâ€ is defined as an IGA score of â€œclearâ€ (score=0) or â€œalmost clearâ€ (score=1) AND at least a two -point improvement in IGA compared to Baseline.  
 P2: An analysis of covariance (ANCOVA) will be used to compare the absolute change 
from Baseline in non -inflammatory lesion count in each treatment group at Week 12, with 
treatment and analysis center as fixed effects an d the Baseline non- inflammatory lesion 
count as the covariate.  
 P3: An ANCOVA will be used to compare the absolute change from Baseline in 
inflammatory lesion count in each treatment group at Week 12, with treatment and analysis center as fixed effects and  the Baseline inflammatory lesion count as the covariate.  
[IP_ADDRESS] Secondary Efficacy Analysis  
Hypothesis tests on the secondary endpoints will be conducted in hierarchical order for S1 through S4.  S1: An ANCOVA will be used to compare the absolute change from Bas eline in total lesion 
counts in each treatment group at Week 12, with treatment and analysis center as fixed effects and the Baseline total lesion count as the covariate.  
 S2: An ANCOVA will be used to compare the percent change from Baseline in total lesi on 
counts in each treatment group at Week 12, with treatment and analysis center as fixed effects and the Baseline total lesion count as the covariate.  
 S3: An ANCOVA will be used to compare the percent change from Baseline in non-
inflammatory lesion count s in each treatment group at Week 12, with treatment and 
analysis center as fixed effects and the Baseline non -inflammatory lesion count as the 
covariate.  
Product Name: [CONTACT_229808] 17Î±- Propi[INVESTIGATOR_16847] (CB -03-01) Protocol: CB-03-01/25 
Sponsor Name: [CONTACT_229771] S.p.A.  Protocol Date: August 06, 2015 
 
CONFIDENTIAL  Page 43 of 55 
TI SOP 305 -A Protocol Template, Version 06   
S4: An ANCOVA will be used to compare the percent change from Baseline in 
inflammatory lesion counts  in each treatment group at Week 12, with treatment and 
analysis center as fixed effects and the Baseline inflammatory lesion count as the covariate.  
[IP_ADDRESS] Imputation of Missing Data  
Missing values for the primary endpoint in the ITT analyses will be imputed by 
â€¢ Multiple imputation using missing at random assumption;  
â€¢ Missing at worst value (for the entire set); 
â€¢ Worst case;  
â€¢ Last observation carried forward; and 
â€¢ Baseline observation carried forward. 
[IP_ADDRESS] Sensitivity Analyses  
Sensitivity analyses will be performed to investigate the robustness of the results obtained 
on the ITT set for the primary endpoints. The first sensitivity analysis will be the Per Protocol analysis. Four additional sensitivity analyses will be performed using different methods of imputation on t he ITT set. On a per -subject basis, missing values for the 
primary endpoints will be imputed with the  
1) Worst value (for the entire set);  
2) Worst case;  
3) Last observation carried forward; and 
4) Baseline observation carried forward. 
[IP_ADDRESS] Multicenter Studies  
Each center will conduct the clinical study under a common protocol. Consistency in study 
execution at each center will be emphasized. The study is to be conducted in such a manner as to have a minimum of eight ITT subjects enrolled in each of the treatment groups at each 
center (i.e., 16 ITT subjects enrolled overall per study center). In the event that there are too few subjects in a treatment arm for a center, then this centerâ€™s data will be combined with another centerâ€™s data in order to achieve the desired minimum  number of subjects per 
treatment arm. The combining of data across centers will be accomplished by [CONTACT_229788]. The sequence of combination will be based on the total number of subjects enrolled in each center (combining the lowest with second lowest and so on). Combining center data to achieve sufficient subjects per treatment arm will result in combined centers. T hese combined centers, as well as 
individual centers with sufficient subjects per treatment arm, will be referred to as â€œanalysis centersâ€ in the statistical analysis.  
Product Name: [CONTACT_229808] 17Î±- Propi[INVESTIGATOR_16847] (CB -03-01) Protocol: CB-03-01/25 
Sponsor Name: [CONTACT_229771] S.p.A.  Protocol Date: August 06, 2015 
 
CONFIDENTIAL  Page 44 of 55 
TI SOP 305 -A Protocol Template, Version 06  [IP_ADDRESS] Multiple Comparisons/Multiplicity  
All the hypothesis tests for the primary endpoints ha ve to be performed at the same 
significance level Î±=0.[ADDRESS_276547] for the secondary endpoints will be performed at the same significance level Î±=0.05 two -sided of the primary endpoints if and only if all the null hypotheses on 
the primary endpoints are rejected.  
[IP_ADDRESS] Subgroup Analyses 
No subgroup analyses are planned. 
17.3.2  Treatment Compliance and Extent of Exposure Analyses  
[IP_ADDRESS] Treatment Compliance  
Compliance to the test article will be evaluated at each visit  and overall according to the 
following formula: 
100  Ã—  ð‘ð‘ð‘ð‘ð‘ð‘ð‘ð‘ð‘ð‘ð‘ð‘  ð‘œð‘œð‘œð‘œ ð‘Žð‘Žð‘Žð‘Žð‘Žð‘Žð‘ð‘ð‘Žð‘Žð‘Žð‘Ž 
ð‘Žð‘Žð‘Žð‘Žð‘Žð‘Žð‘Žð‘Žð‘Žð‘Žð‘Žð‘Žð‘Žð‘Žð‘Žð‘Žð‘Žð‘Ž ð‘œð‘œð‘Žð‘Žð‘Žð‘Ž
ð‘ð‘ð‘ð‘ð‘ð‘
ð‘ð‘ð‘ð‘ð‘ð‘ ð‘œð‘œð‘œð‘œ ð‘Žð‘Žð‘Žð‘Žâ„Žð‘ð‘ð‘’ð‘’ð‘ð‘ð‘Žð‘Žð‘ð‘ð‘’ð‘’ ð‘Žð‘Žð‘Žð‘Ž
ð‘Žð‘Žð‘Žð‘Žð‘Žð‘Žð‘Žð‘Žð‘Žð‘Žð‘Žð‘Žð‘Žð‘Žð‘œð‘œð‘Žð‘Žð‘Žð‘Ž 
Non-compliance will be defined as a compliance value less than 80%.  
 Descriptive stat istics will be used to summarize test article compliance at each visit and 
overall for the ITT and PP sets. The proportion of compliant and non- compliant subjects 
will be summarized by [CONTACT_229789]. Subjects with an overall compliance not evaluable (due to missing data) or less than 
80% will be excluded from the PP set. 
[IP_ADDRESS] Extent of Exposure 
Descriptive statistics will be used to summarize exposure to test article for the ITT, PP and 
Safety sets. The total amount of test article used (grams applied) will be calculated for each 
subject from the weights of the returned test articles. The mean daily amount of test article applied (total amount of test article used/number of days of treatment) will be calc ulated 
for each subject and summarized by [CONTACT_53846].  
Product Name: [CONTACT_229808] 17Î±- Propi[INVESTIGATOR_16847] (CB -03-01) Protocol: CB-03-01/25 
Sponsor Name: [CONTACT_229771] S.p.A.  Protocol Date: August 06, 2015 
 
CONFIDENTIAL  Page 45 of 55 
TI SOP 305 -A Protocol Template, Version 06  17.3.3  Safety Analyses 
[IP_ADDRESS] Local Skin Reactions (LSRs) 
LSRs (telangiectasia, skin atrophy, striae rubrae, erythema, edema, scaling/dryness, 
stinging/burning, and pruritus) will be summarized by [CONTACT_229790].  
[IP_ADDRESS] Adverse Events (AEs)  
Pre-treatment AEs (PTAEs) and Treatment Emergent AEs (TEAEs) will be coded using 
the MedDRA coding dictionary. TEAEs will be summarized by [CONTACT_6654]. The number and proportion of subjects with any TEAE and the number of TEAEs will be tabulated by [CONTACT_55366], seriousness, relationship to test article, and severity.  
[IP_ADDRESS] Electrocardiograms (ECGs)  
ECGs will be evaluated for any  material change during the study period. Results 
(normal/borderline/abnormal) of the ECG and descriptive statistics will be provided by [CONTACT_229791], RR duration, PR duration, QRS duration, QT duration including Bazettâ€™s and Fridericiaâ€™s corrections, and P axis for the Safety set. Changes in overall interpretation (normal/abnormal/borderline) of the ECG from Baseline to Week 12 will be examined using shift tables. 
[IP_ADDRESS] Vital Signs  
Vital signs will be listed and summarized by [CONTACT_1570]. Descriptive statistics (mean, 
standard deviation, CV%, minimum, median, and maximum) will be presented. 
[IP_ADDRESS] Urine Pregnancy Tests  
The results of UPTs monthly at Visit 1 (Baseline), Visit 2 (Week 4), Visit 3 (Week 8), and 
Visit 4 (Week 12 / end of treatment), or if the subject withdraws prematurely,  will be listed.  
17.4 Interim Analyses  
No interim statistical analyses are planned.  
18. ETHICAL AND REGULATORY CONSIDERATIONS  
18.1 Compliance with Good Clinical Research Practice  
This study will be conducted in compliance with the principles of the Declaration of Helsinki, with the current Good Clinical Practice (GCP) guidelines and with other applicable regulations. The investigator and all study staff will conduct the study in 
Product Name: [CONTACT_229808] 17Î±- Propi[INVESTIGATOR_16847] (CB -03-01) Protocol: CB-03-01/25 
Sponsor Name: [CONTACT_229771] S.p.A.  Protocol Date: August 06, 2015 
 
CONFIDENTIAL  Page 46 of 55 
TI SOP 305 -A Protocol Template, Version 06  compliance with this protocol. The protocol, informed consent/assent documents, 
recruitment advertisements and any amendments to these items will have IRB approval prior to study initiation. Voluntary informed consent/assent will be given by [CONTACT_229792]â€™s parent/guardian prior to the initiation of any study -related procedures. 
The rights, safety, and well -being of the study subjects are the most important 
considerations and prevail over the interests of science and society. All personnel involved in the conduct of this study must  be qualified by [CONTACT_8640], training, and experience to 
perform their assigned responsibilities.  
18.[ADDRESS_276548] (IRB) and Informed Consent/Assent  
Before study initiation, the investigator must have written and dated approval from the IRB for th e protocol, consent/assent form, subject recruitment materials/process (e.g., 
advertisements), and any other written information to be provided to subjects and the subjectâ€™s parent/guardian. The investigator should also provide the IRB with a copy of the product labeling, information to be provided to subjects/care givers and any updates. The investigator will submit documentation of the IRB approval to TI.  The IRB approved consent/assent form must include all elements required by [CONTACT_8415], state, and local reg ulations, and may include appropriate additional elements. 
 The investigator/designee will explain the study to each potential subject and the subjectâ€™s parent/guardian. The subject must indicate voluntary consent/assent by [CONTACT_229793]/assent form. The parent or legal guardian must provide written informed consent for the subject. The investigator must provide the subject with a copy of the consent/assent form, in a language the subject understands.   The investigator wi ll maintain documentation that informed consent/assent was obtained 
prior to the initiation of any study -specific procedures.  
18.[ADDRESS_276549] be sent to TI.  
 New or altered consent/assent forms required by [CONTACT_59206] a protocol change must be signed by [CONTACT_229794]â€™s parent/guardian currently enrolled in the study and 
must be used for any subsequent subject enrollment. 
Product Name: [CONTACT_229808] 17Î±- Propi[INVESTIGATOR_16847] (CB -03-01) Protocol: CB-03-01/25 
Sponsor Name: [CONTACT_229771] S.p.A.  Protocol Date: August 06, 2015 
 
CONFIDENTIAL  Page 47 of 55 
TI SOP 305 -A Protocol Template, Version 06  18.5 Study Monitoring  
Representatives of TI and/or the Sponsor must be allowed to visit all study sites, to review 
study records, and to directly compare them with source documents (including, but not limited to patient and hospi[INVESTIGATOR_1097]), to discuss the study conduct with the investigator and study staff, and to verify that the investigator, study staff, and facilities remain acceptable for the conduct of the study.  
 Representatives of government regulatory authorities may also evaluate the study records, 
source documents, investigator, study staff, and facilities.  The investigator should immediately notify TI of any audits of this study by [CONTACT_229795][INVESTIGATOR_28221]. 
18.6 Case Report Form Requirements: Electronic Data Capture (EDC)  
The study will utilize validated 21CFR Part [ADDRESS_276550]â€™s CRF. Individuals who will be providing electronic signatures must first s ubmit 
documentation with a handwritten signature [CONTACT_28285] a legally binding equivalent to their handwritten signature.  
18.[ADDRESS_276551] 
The investigator should provide the IRB with reports, updates, and other information (e.g., safety updates, protocol amendments, and administrative letters) according to regulatory requirements or Institution procedures. 
18.8 Quality Assurance Audits  
Representatives from TI and/or the Sponsor or a third party selected by [CONTACT_229796] a quality assurance (QA) audit of this study. During the audit, the investigator must provide the auditor with direct access to all relevant documents and discuss any findings with the auditor.  
Product Name: [CONTACT_229808] 17Î±- Propi[INVESTIGATOR_16847] (CB -03-01) Protocol: CB-03-01/25 
Sponsor Name: [CONTACT_229771] S.p.A.  Protocol Date: August 06, [ADDRESS_276552] maintain all study records (including test article disposition, 
informed consents/assents, CRFs and data clarification forms, if paper CRFs, source documents, correspondence, regulatory documents, contracts, etc.) for the maximum period required by [CONTACT_229797], whichever is longer. The Study Medication Accountability Logs will be collected at the end of the study and kept with the study records. Copi[INVESTIGATOR_229768].  The investigator must contact [CONTACT_229798].  
 If the investigator withdraws from the study, the records shall be transferred to a mutually agreed upon designee. Written notification of such a transfer must be given to TI. 
18.[ADDRESS_276553]â€™s parent/guardian (if appropriate), except as necessary for monitoring by [CONTACT_229799], the FDA or other regulatory authority, or the IRB.  The investigator and all employees and coworkers involved with this study shall not disclose or use for any purpose other than performance of the study, any data, records, or other unpublished, confidential information disclosed to those individuals for the purpose of the study. Prior written agreement from TI or the Sponsor must be obtained for the disclosure of any said confidential information to other parties. 
19. REFERENCES  
1. Celasco G, Moro, L, Bozzella R, Ferraboschi P, Bartorelli L, Quat trocchi C, Nicoletti 
F. Biological profile of cortexolone 17Î± -propi[INVESTIGATOR_16847] (CB -03-01), a new topi[INVESTIGATOR_229769].  Arzneim. -Forsch. 2004; 54, 881-886. 
 
2. 171-7151- 201. A Phase 2, Multicenter, Randomized, Double -Blind, Vehicle -
Controlled, Dose Escalating Study to Evaluate the Safety and Efficacy of Cortexolone 17Î±-Propi[INVESTIGATOR_16847] (CB -03-01) Cream Applied Once or Twice -Daily for [ADDRESS_276554] Name: [CONTACT_229808] 17Î±- Propi[INVESTIGATOR_16847] (CB -03-01) Protocol: CB-03-01/25 
Sponsor Name: [CONTACT_229771] S.p.A.  Protocol Date: August 06, 2015 
 
CONFIDENTIAL  Page 49 of 55 
TI SOP 305 -A Protocol Template, Version 06  APPENDIX 1  SAMPLE SUBJEC T AND PARENT/GUARDIA N 
INSTRUCTION SHEET  
Copi[INVESTIGATOR_229770]. This sample instruction sheet may be used or modified by [CONTACT_093]. If the instruction sheet is modified other than  to reflect appropriate contact [CONTACT_229800], the Subject Instruction Sheet will need to be reviewed and approved by [CONTACT_229801].  The investigator should provide a copy of the Subject Instruction Sheet to each subject and the subjectâ€™s parent/guardian at Visit [ADDRESS_276555] article(s).  
  
Product Name: [CONTACT_229808] 17Î±- Propi[INVESTIGATOR_16847] (CB -03-01) Protocol: CB-03-01/25 
Sponsor Name: [CONTACT_229771] S.p.A.  Protocol Date: August 06, [ADDRESS_276556] AND PARENT/GUARDIAN INSTRUCTION SHEET  
Please follow these instructions carefully.  If you do not understand anything in these 
instructions, ask your parent or guardian for help. Contact/ask your parent or guardian to contact [CONTACT_229802]: 
Contact:        [CONTACT_229803]:     
 
STUDY MEDICATION APPLICATION:  
â€¢ YOU WILL BE INSTRUCTED HOW TO APPLY THE STUDY MEDICATION IN THE 
CLINIC TWICE -DAILY: Once in the morning and once in the evening daily with 
approximately eight (8) hours or more between applications.  
â€¢ WASH YOUR ENTIRE FACE WITH MILD SOAP AND WATER AND GENTLY DRY  
THE AREA TO BE TREATED.  
â€¢ WASH YOUR HANDS BEFORE AND AFTER APPLYIN G THE CREAM.  
â€¢ DISPENSE ABOUT 1 GRAM OF CREAM ONTO ONE OF YOUR FINGERTIPS AND 
THEN BEGIN TO APPLY THE CREAM TO YOUR ENTIRE FACE BY [CONTACT_229804]  (FOREHEAD, CHEEKS, 
NOSE, AND CHIN).  
â€¢ SPREAD THE CREAM EVENLY WITH YOUR FINGER TIP TO COVER YOUR ENTIRE  
FACE  WITH A VERY THIN EVEN COAT OF THE CREAM AS DIRECTED BY [CONTACT_229805].  
â€¢ RECORD DATE AND TIME  OF STUDY MEDICATION APPLICATION IN YOUR 
SUBJECT DIARY.  
â€¢ DO NOT WASH THE TREATED AREA FOR AT LEAST FOUR (4) HOURS AFT ER 
APPLICATION OR COVER  OR WRAP AREAS WHERE STUDY MEDICATION WAS  
APPLIED.  
â€¢ CONTINUE USE OF T HE STUDY MEDICATION AS DIRECTED BY [CONTACT_64918] S TUDY 
DOCTOR.  
 
BEFORE EACH STUDY VISIT: 
â€¢ DO NOT APPLY THE STUDY MEDICATION WITHIN FOUR (4) HOUR S OF YOUR 
SCHEDULED STUDY VISI T. 
 
ADDITIONAL REMINDERS : 
â€¢ Store the study medications according to the instructions on the la bel. 
â€¢ Bring this sheet, the Subject Diary, and ALL your containers (used and unused) of study 
medication with you to every  study visit.  
â€¢ Do not allow anyone else to use the study medications and keep the containers of study medication away from children/pets. 
â€¢ Discontinue use if skin irritation or rash develop and contact [CONTACT_3452].  
 
STUDY VISIT SCHEDULE :  
VISIT 2:  
Date:                        Time:                                   VISIT 3:  
Date:                        Time:                                   
VISIT 4:  
Date:                        Time:                                    
Product Name: [CONTACT_229808] 17Î±- Propi[INVESTIGATOR_16847] (CB -03-01) Protocol: CB-03-01/25 
Sponsor Name: [CONTACT_229771] S.p.A.  Protocol Date: August 06, [ADDRESS_276557] and parent/guardian (if applicable) at 
Visit 1 (Day 1, Baseline) and all follow -up visits as necessary.  
Product Name: [CONTACT_229808] 17Î±- Propi[INVESTIGATOR_16847] (CB -03-01) Protocol: CB-03-01/25 
Sponsor Name: [CONTACT_229771] S.p.A.  Protocol Date: August 06, [ADDRESS_276558] DIARY for PROTOCOL CB -03-01/[ADDRESS_276559] the date and time. If you miss a dose, write MISSED in the space for time.  
Return this diary, your used AND unused medication tubes at each visit. AS REQUIRED, PARENT/GUARDIAN SHOULD ASSIST IN 
RECORDING THE SUBJECT DIARY.  
 If you  have any questions, call: Name:   __________________________  Telephone: ______________________  
Date  
(dd/MMM/yy)  Dose  
(time of day)  Date  
(dd/MMM/yy)  Dose  
(time of day)  
____/_____/____  _____ : ___ __am  ___ ___ : ___ __pm  ____/_____/____  _____ : ___ __am  ___ ___ : ___ __pm  
____/_____/____  ___ ___ : ___ __am  ___ ___ : ___ __pm  ____/_____/____  ___ ___ : ___ __am  ___ ___ : ___ __pm  
____/_____/____  ___ ___ : ___ __am  ___ ___ : ___ __pm  ____/_____/____  ___ ___ : ___ __am  ___ ___ : ___ __pm  
____/_____/____  ___ ___ : ___ __am  ___ ___ : ___ __pm  ____/_____/____  ___ ___ : ___ __am  ___ ___ : ___ __pm  
____/_____/____  ___ ___ : ___ __am  ___ ___ : ___ __pm  ____/_____/____  ___ ___ : ___ __am  ___ ___ : ___ __pm  
____/_____/____  ___ ___ : ___ __am  ___ ___ : ___ __pm  ____/_____/____  ___ ___ : ___ __am  ___ ___ : ___ __pm  
____/_____/____  ___ ___ : ___ __am  ___ ___ : ___ __pm  ____/_____/____  ___ ___ : ___ __am  ___ ___ : ___ __pm  
____/_____/____  ___ ___ : ___ __am  ___ ___ : ___ __pm  ____/_____/____  ___ ___ : ___ __am  ___ ___ : ___ __pm  
____/_____/____  ___ ___ : ___ __am  ___ ___ : ___ __pm  ____/_____/____  ___ ___ : ___ __am  ___ ___ : ___ __pm  
____/_____/____  ___ ___ : ___ __am  ___ ___ : ___ __pm  ____/_____/____  ___ ___ : ___ __am  ___ ___ : ___ __pm  
____/_____/____  ___ ___ : ___ __am  ___ ___ : ___ __pm  ____/_____/____  ___ ___ : ___ __am  ___ ___ : ___ __pm  
____/_____/____  ___ ___ : ___ __am  ___ ___ : ___ __pm  ____/_____/____  ___ ___ : ___ __am  ___ ___ : ___ __pm  
____/_____/____  ___ ___ : ___ __am  ___ ___ : ___ __pm  ____/_____/____  ___ ___ : ___ __am  ___ ___ : ___ __pm  
____/_____/____  ___ ___ : ___ __am  ___ ___ : ___ __pm  ____/_____/____  ___ ___ : ___ __am  ___ ___ : ___ __pm  
Next appointment: _____________, ______/________/_____ at ________am/pm  
                                 Week Day               dd        MMM      yy  
Site Use Only:  Diary Dispensed at Visit:   
  1 (Baseline)   2 (Week 4)   3 (Week 8)  Date Dispensed:  Date Returned:  
Product Name: [CONTACT_229808] 17Î±- Propi[INVESTIGATOR_16847] (CB -03-01) Protocol: CB-03-01/25 
Sponsor Name: [CONTACT_229771] S.p.A.  Protocol Date: August 06, [ADDRESS_276560] articles will be packaged and labeled by [CONTACT_16015]. CB-03-01 cream, 
1% will be packaged in blind- end epoxy lined aluminum tubes, with a polypropylene cap 
closure, containing [ADDRESS_276561] Boxes and Labels  
The randomization scheme will be blocked by [CONTACT_76537]. The box label will, at a minimum, contain the following information: protocol number, subject identifiers (subject number), the contents, an investigational test article disclaimer (e.g., Caution: New Drug Limited by [CONTACT_120906]), and the appropriate storage conditions 
for the test article.  
 
Subject Kits and Labels  
Each Subject Kit label will, at a minimum, contain the following information: protocol number, subject identifiers (subject number and subject initials to be filled in), the contents, the kit number , an investigational test article disclaimer (e.g., Caution: New Drug Limited 
by [CONTACT_120906]), and the appropriate storage conditions for the test article. In the event of an emergency, the contents of the kit can be unblinded using the proper procedures as outlined in the protocol and by [CONTACT_229806].  Kits will be dispensed at Baseline, Visit 2 (Week 4), and Visit 3 (Week 8). Subjects should not have more than one (1) kit at any time. When the kits are dispensed to subjects, the Subject Kit label should be completed entirely with the necessary information recorded in the Study Medication Accountability Log at the investigative site.  
 
Tube Labels  
Each tube will contain, at a minimum, the following informatio n: the protocol number, 
subject identifiers (subject number), the contents, the tube number (with test article batch number and retest date), an investigational test article disclaimer (e.g., Caution: New Drug Limited by [CONTACT_229807] l use), and the appropriate storage conditions 
for the test article.  
A 3.[ADDRESS_276562] Name: [CONTACT_229808] 17Î±- Propi[INVESTIGATOR_16847] (CB -03-01) Protocol: CB-03-01/25 
Sponsor Name: [CONTACT_229771] S.p.A.  Protocol Date: August 06, [ADDRESS_276563] will also be instructed to bring all the tubes (used and unused) to each clinic visit. When a subject returns each used tube of test article, record the date of return, and initials of the individual accepting the return for each tube of test article on the same line of the Study Medication Accountability Log as the dispensing information.  At Visit 2 and Visit 3 (Week 4 and Week 8), visually check the tubes of test article to 
determine if the subject has applied correctly the test article and, if necessary, review the application instructions with the subject. Any discrepancies or concerns with the subject regarding the use of the diary to record test article complia nce should be addressed. 
 At Visits 2, 3, and 4 (Weeks 4, 8 and 12), record the weights of all returned tubes to the nearest tenth gram (0.1 gram). At each visit, all tubes should be collected and additional tubes dispensed to the subject to ensure each subject has sufficient test article for the designated treatment period. Make every effort to obtain the return of all dispensed tubes of test article. If these efforts fail, make a detailed note of the reason for the failure in the source documents and on t he Comments page of the CRFs.  
A 3.[ADDRESS_276564] comply with applicable regulations and guidelines, and should include: 
â€¢ Amount received placed in storage area.  
â€¢ Amount currently in storage area. 
â€¢ Label ID number (subject kit number). 
â€¢ Dates and initials of the person responsible for each product inventory 
entry/movement. 
â€¢ Amount dispensed to and returned by [CONTACT_6992], including unique subject identifiers.  
Product Name: [CONTACT_229808] 17Î±- Propi[INVESTIGATOR_16847] (CB -03-01) Protocol: CB-03-01/25 
Sponsor Name: [CONTACT_229771] S.p.A.  Protocol Date: August 06, 2015 
 
CONFIDENTIAL  Page 55 of 55 
TI SOP 305 -A Protocol Template, Version 06  â€¢ Amount transferred to another area for dispensing or storage. 
â€¢ Non-study disposition (e.g., lost, wasted, broken). 
â€¢ Amount returned to Sponsor or third party (if applicable). 
â€¢ Amount destroyed at st udy site, if applicable.  
 
TI will provide forms to facilitate inventory control if the staff at the study site does not have an established system that meets these requirements.  
A 3.[ADDRESS_276565] the study site. In the event that the investigator believes dose 
modification is necessary (e.g., problems with tolerance), the subjectâ€™s care should be 
discussed with the Medical Monitor prior to making any dose modifications. All dose modifications must be reported on the appropriate CRF .
 
A 3.[ADDRESS_276566] any changes from the application specified in the protocol (e.g., missed applications, investigator directed reduction in application frequency, etc.). The date and time of the last application of the test article will be recorded on a CRF.  A Subject Diary will be dispensed to subjects to record the dates and times of all application doses and to record a ny missed doses of the test article ( Appendix 2). Subjects will be 
instructed to bring the diary with them to each study visit.  
A 3.[ADDRESS_276567] tenth gram (0.1g) in order to document extent of subject exposure. Unless instructed otherwise by [CONTACT_1034], the study site will keep the original Study Medication Accountability Log in the study file. A copy of the Study Medication Accountability  Log will be returned to the Sponsor. All 
tubes of test article will then either be a) returned to the study Sponsor or b) emptied and provided to a sponsor -identified third party vendor for appropriate destruction, according 
to applicable regulations  with  the provision of a certificate of destruction. 